Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 83
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

DNA methylation and stroke prognosis, an epigenome-wide association study

  • Jiménez-Balado, Joan|||0000-0003-4125-9134
  • Fernandez-Perez, Isabel|||0000-0002-9949-1393
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Lazcano, Uxue|||0000-0003-3948-3372
  • Soriano Tárraga, Carolina|||0000-0002-5635-273X
  • Vallverdú-Prats, Marta|||0000-0002-5262-817X
  • Mola-Caminal, Marina
  • Rey-Álvarez, Lucía|||0000-0003-3000-4814
  • Macias Gómez, Adrià|||0000-0003-0926-681X
  • Suárez-Pérez, Antoni|||0000-0002-0832-7580
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • Rodriguez Campello, Ana Maria|||0000-0001-8621-1420
  • Cuadrado Godia, Elisa|||0000-0002-9147-875X
  • Ois, Angel|||0000-0002-1375-5950
  • Esteller, M.|||0000-0003-4490-6093
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
Background and aims: Stroke is the leading cause of adult-onset disability. Although clinical factors influence stroke outcome, there is a significant variability among individuals that may be attributed to genetics and epigenetics, including DNA methylation (DNAm). We aimed to study the association between DNAm and stroke prognosis. Methods and results: To that aim, we conducted a two-phase study (discovery-replication and meta-analysis) in Caucasian patients with ischemic stroke from two independent centers (BasicMar [discovery, N = 316] and St. Pau [replication, N = 92]). Functional outcome was assessed using the modified Rankin Scale (mRS) at three months after stroke, being poor outcome defined as mRS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MFG-E8 (LACTADHERIN), a novel marker associated with cerebral amyloid angiopathy

  • Marazuela, Paula|||0000-0003-1038-5242
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Camacho, Jessica|||0000-0001-8018-8274
  • Martinez-Saez, Elena|||0000-0001-6004-5364
  • Kuiperij, H. Bea
  • Verbeek, Marcel M.
  • De Kort, Anna M.|||0000-0002-5679-516X
  • Schreuder, Floris H. B. M.
  • Klijn, Catharina J. M.
  • Castillo-Ribelles, Laura|||0000-0001-9380-7839
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Pujadas, Francesc|||0000-0003-3569-2601
  • Delgado Martínez, María Pilar|||0000-0002-1628-4488
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
  • Pizarro, Jesús
The online version contains supplementary material available at 10.1186/s40478-021-01257-9.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke

  • Puig, Josep
  • Blasco, Gerard
  • Daunis-i-Estadella, Pepus
  • van Eendenburg, Cecile
  • Carrillo-García, María
  • Aboud, Carlos
  • Hernández-Pérez, María
  • Serena, Joaquín
  • Biarnés, Carles
  • Nael, Kambiz
  • Liebeskind, David S.
  • Thomalla, Götz
  • Menon, Bijoy K.
  • Demchuk, Andrew M.
  • Wintermark, Max
  • Pedraza, Salvador
  • Castellanos, María del Mar
[Abstract] Objective: Blood-brain barrier (BBB) permeability has been proposed as a predictor of hemorrhagic transformation (HT) after tissue plasminogen activator (tPA) administration; however, the reliability of perfusion computed tomography (PCT) permeability imaging for predicting HT is uncertain. We aimed to determine the performance of high-permeability region size on PCT (HPrs-PCT) in predicting HT after intravenous tPA administration in patients with acute stroke. Methods: We performed a multimodal CT protocol (non-contrast CT, PCT, CT angiography) to prospectively study patients with middle cerebral artery occlusion treated with tPA within 4.5 hours of symptom onset. HT was graded at 24 hours using the European-Australasian Acute Stroke Study II criteria. ROC curves selected optimal volume threshold, and multivariate logistic regression analysis identified predictors of HT. Results: The study included 156 patients (50% male, median age 75.5 years). Thirty-seven (23,7%) developed HT [12 (7,7%), parenchymal hematoma type 2 (PH-2)]. At admission, patients with HT had lower platelet values, higher NIHSS scores, increased ischemic lesion volumes, larger HPrs-PCT, and poorer collateral status. The negative predictive value of HPrs-PCT at a threshold of 7mL/100g/min was 0.84 for HT and 0.93 for PH-2. The multiple regression analysis selected HPrs-PCT at 7mL/100g/min combined with platelets and baseline NIHSS score as the best model for predicting HT (AUC 0.77). HPrs-PCT at 7mL/100g/min was the only independent predictor of PH-2 (OR 1, AUC 0.68, p = 0.045). Conclusions: HPrs-PCT can help predict HT after tPA, and is particularly useful in identifying patients at low risk of developing HT., This work was partially supported by grants from the Spanish Ministry of Health, Instituto de Investigación Carlos III (PI10/01309 and PI13/02258), the ERDF: European Regional Development Fund and the Spanish Stroke Research Network (INVICTUS), also financed by the Instituto de Salud Carlos III (RD12/0014/0001 and RD16/0019/0004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Random Forest-Based Prediction of Stroke Outcome

  • Fernández-Lozano, Carlos
  • Hervella, Pablo
  • Mato-Abad, Virginia
  • Rodríguez-Yáñez, Manuel
  • Suárez-Garaboa, Sonia
  • López-Dequidt, Iria
  • Estany-Gestal, Ana
  • Sobrino, Tomás
  • Campos, Francisco
  • Castillo, José
  • Rodríguez-Yáñez, S.
  • Iglesias Rey, Ramón
[Abstract] We research into the clinical, biochemical and neuroimaging factors associated with the outcome of stroke patients to generate a predictive model using machine learning techniques for prediction of mortality and morbidity 3-months after admission. The dataset consisted of patients with ischemic stroke (IS) and non-traumatic intracerebral hemorrhage (ICH) admitted to Stroke Unit of a European Tertiary Hospital prospectively registered. We identified the main variables for machine learning Random Forest (RF), generating a predictive model that can estimate patient mortality/morbidity according to the following groups: (1) IS + ICH, (2) IS, and (3) ICH. A total of 6022 patients were included: 4922 (mean age 71.9 ± 13.8 years) with IS and 1100 (mean age 73.3 ± 13.1 years) with ICH. NIHSS at 24, 48 h and axillary temperature at admission were the most important variables to consider for evolution of patients at 3-months. IS + ICH group was the most stable for mortality prediction [0.904 ± 0.025 of area under the receiver operating characteristics curve (AUC)]. IS group presented similar results, although variability between experiments was slightly higher (0.909 ± 0.032 of AUC). ICH group was the one in which RF had more problems to make adequate predictions (0.9837 vs. 0.7104 of AUC). There were no major differences between IS and IS + ICH groups according to morbidity prediction (0.738 and 0.755 of AUC) but, after checking normality with a Shapiro Wilk test with the null hypothesis that the data follow a normal distribution, it was rejected with W = 0.93546 (p-value < 2.2e−16). Conditions required for a parametric test do not hold, and we performed a paired Wilcoxon Test assuming the null hypothesis that all the groups have the same performance. The null hypothesis was rejected with a value < 2.2e−16, so there are statistical differences between IS and ICH groups. In conclusion, machine learning algorithms RF can be effectively used in stroke patients for long-term outcome prediction of mortality and morbidity., This study was partially supported by grants from the Spanish Ministry of Science and Innovation (SAF2017-84267-R), Xunta de Galicia (Axencia Galega de Innovación (GAIN): IN607A2018/3), Instituto de Salud Carlos III (ISCIII) (PI17/00540, PI17/01103), Spanish Research Network on Cerebrovascular Diseases RETICS-INVICTUS PLUS (RD16/0019) and by the European Union FEDER program. T. Sobrino (CPII17/00027), F. Campos (CPII19/00020) are recipients of research contracts from the Miguel Servet Program (Instituto de Salud Carlos III). General Directorate of Culture, Education and University Management of Xunta de Galicia (ED431G/01,252 ED431D 2017/16), “Galician Network for Colorectal Cancer Research" (Ref. ED431D 2017/23), Competitive Reference Groups (ED431C 2018/49), Spanish Ministry of Economy and Competitiveness via funding of the unique installation BIOCAI (UNLC08-1E-002, UNLC13-13–3503), European Regional Development Funds (FEDER)., Xunta de Galicia; IN607A2018/3, Xunta de Galicia; ED431G/01,252, Xunta de Galicia; ED431D 2017/16
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Abrogating mitochondrial ROS in neurons or astrocytes reveals cell-specific impact on mouse behaviour

  • Vicente-Gutiérrez, Carlos
  • Bonora, Nicoló
  • Jimenez-Blasco, Daniel
  • López-Fabuel, Irene
  • Bates, Georgina
  • Murphy, Michael P.
  • Almeida, Angeles
  • Bolaños, Juan P.
Cells naturally produce mitochondrial reactive oxygen species (mROS), but the in vivo pathophysiological significance has long remained controversial. Within the brain, astrocyte-derived mROS physiologically regulate behaviour and are produced at one order of magnitude faster than in neurons. However, whether neuronal mROS abundance differentially impacts on behaviour is unknown. To address this, we engineered genetically modified mice to down modulate mROS levels in neurons in vivo. Whilst no alterations in motor coordination were observed by down modulating mROS in neurons under healthy conditions, it prevented the motor dis- coordination caused by the pro-oxidant neurotoxin, 3-nitropropionic acid (3-NP). In contrast, abrogation of mROS in astrocytes showed no beneficial effect against the 3-NP insult. These data indicate that the impact of modifying mROS production on mouse behaviour critically depends on the specific cell-type where they are generated., J.P.B. is funded by the Agencia Estatal de Investigación (SAF2016-78114-R, PID2019-105699RB-I00/AEI/10.13039/501100011033 and RED2018-102576-T), Plan Nacional sobre Drogas (2020I028), ISCIII (CB16/10/00282), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Bio-medicina 2017 Fundación BBVA and Fundación Ramón Areces. A.A. is unded by the ISCIII (PI18/00265, RD16/0019/0018), AEI (PI18/00265, RD16/0019/0018) and European Union’s Horizon 2020 Research and Innovation Program (Grant Agreement 686009). J.P.B. and A.A. are fundedby the grant CSI151P20 from the Junta de Castilla y Leon., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

APC/C-Cdh1 inhibition promotes hypomyelination during postnatal development

  • Gomila Huguet, Silvia
  • Bobo-Jimenez, Veronica
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
Resumen de la conferencia presentada al 19 Congreso Nacional de la Sociedad española de neurociencia, celebrada en Lleida del 3 al 5 de noviembre de 2021, The E3 ubiquitin ligase APC/C-Cdh1 plays a key role in the developing brain, where it regulates the onset of neurogenesis during gestation (Delgado-Esteban et al, 2013). Whereas neurogenesis is complete at birth, synaptogenesis and myelination occurs during the postnatal brain growth. Recently, we described a novel human missense mutation in Cdh1 protein, which results in microcephaly, psychomotor retardation and refractory epilepsy (Rodríguez et al, 2019), alterations directly related to synapse dysfunction and hypomyelination (Repudi et al, 2021). Moreover, the APC/C-Cdh1 target, Rock2 (Bobo-Jiménez et al, 2017), negatively regulates myelination (Muñoz-Esquivel et al, 2019). Here, we study the role of APC/C-Cdh1 activity on oligodendroglial lineage and myelination in the postnatal brain, Funded by ISCIII (PI18/00265; RD16/0019/0018) FEDER; SG is funded by IBSAL and VB is funded by Junta de Castilla y Leon (Escalera de Excelencia CLU-2017-03, Cofinanciada por el P.O. FEDER de Castilla y Leon).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Mitochondrial reactive oxygen species regulate cortical organization in the developing brain

  • Mengual, Regina
  • Rodríguez González, Cristina
  • Bobo-Jimenez, Veronica
  • Delgado-Esteban, María
  • Almeida, Angeles
Trabajo presentado en el 43rd Annual Meeting of the Spanish Society of Biochemistry & Molecular Biology, celebrado en Barcelona, del 19 al 22 de julio de 2021, Reactive oxygen species (ROS) participate as second messengers in different signaling pathways.Then, ROS levels regulation is essential to maintain cell physiological processes and homeostasis. In the central nervous system, ROS play key roles in cell proliferation, neuronal differentiation, and synapse maintenance (1). Moreover, mitochondrial ROS (mROS) generated by astrocytes regulate brain metabolism and behavior in the adult. Specifically, the reduction of astrocytic mROS alters neuronal structure and integrity and causes cognitive impairment (2). However, the impact of mROS generation during brain development is unknown, SCIII :PI18/00265-PI18/00103-RD16/0019/0018-FEDER European regional development fund- JCyL:IES007P17-CLU201703- P.O FEDER CyL1420 and EDU/556/2019.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Cerebral cortex development is coordinated by mitochondrial reactive oxygen species

  • Mengual, Regina
  • Rodríguez González, Cristina
  • Bobo-Jimenez, Veronica
  • Delgado-Esteban, María
  • Bolaños, Juan P.
Trabajo presentado como conferencia invitada en el 19 Congreso Nacional de la SENC, celebrado en Lleida del 3 al 5 de noviembre de 2021, ISCIII: PI18/00103; PI18/00265; RD16/0019/0018; FEDER European regional development fund; JCyL: CSI151P20; CLU201703 P.O.FEDER CyL1420 and EDU/556/2019.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Ischemia-induced oxidative stress triggers DNA double strand breaks leading to neuronal apoptosis

  • Alvarez Coruña, Enrique
  • Hermosín Montes, J. M.
  • Mengual, Regina
  • Delgado-Esteban, María
  • Almeida, Angeles
Poster del trabajo presentado en el 43rd Annual Meeting of the SEBBM, The maintenance of DNA integrity is essential for neuronal homeostasis. Increased oxidative stress and DNA double strand break (DSB) generation occur in neurological diseases, including neurodegenerative diseases and stroke [1]. However, the interplay between both phenomena and their implication in neuronal death is largely unknown. Here, we aim to investigate the impact of ischemia-induced DNA DSB on neuronal death and the role played by oxidative stress on DNA repair. For this purpose, mouse cortical neuron in primary culture were exposed to an experimental model of ischemia in vitro (oxygen-glucose deprivation, OGD) for 30 minutes followed by 4 hours of reoxygenation [1]. Next, we evaluated DNA DSB generation, protein expression and neuronal apoptosis by using western blot, flow cytometry, and immunostaining. We found that OGD time-dependently increased the expression of the DNA DSB marker, phospho-H2AX [2], which paralleled with a higher expression levels of apoptotic markers, active caspase-3 and p53. Moreover, OGD promoted oxidative stress and neuronal apoptosis, as revealed by the increase in both annexin/7AAD staining and TUNEL assay. Finally, to study the implication of oxidative stress in DNA damage, we used neuronal cultures from embryo mice that constitutively express the catalase in the mitochondria (mCAT), which downmodulates the endogenous generation of reactive oxygen species [3]. We found that mCAT neurons were more resistant to OGD-induced DNA damage and neuronal apoptosis than wild type neurons. Our results demonstrate that oxidative stress might play an important role in DNA DSB generation, which is involved in neuronal apoptosis caused by ischemia., ISCIII: PI18/00103;PI18/00285;RD16/0019/0018; FEDER European regional development fund. JCyL: CSI151P20; CLU201703 P.O.FEDER CyL1420 and EDU/556/2019.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Impact of p53 on the microglial response in an in vivo model of amyloid-beta-induced neurodegeneration

  • González Sánchez, Sergio
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
Resumen del trabajo presentado en el 43rd Annual Meeting of the Spanish Society of Biochemistry & Molecular Biology, celebrado en Barcelona, del 19 al 22 de julio de 2021, Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by the presence of amyloid-β (Aβ) and Tau protein aggregates. Although research has classically focused on neuronal alterations, neuroinflammation has emerged as a key factor in AD pathophysiology. The main cellular components involved in the brain inflammatory process are glial cells. Aβ aggregates bind to pattern recognition receptors on microglia and astrocytes, whichtriggers an immune response that contributes to disease progres sion1,2. Functionally, microglia can be classified into M1 proinflammatory/neurotoxic or M2 anti-inflammatory/neuroprotective phenotypes 2. Previously, we described a key role for p53 in Aβ-induced neurodegeneration in vivo3. Recently, p53 has emerged as a modulator of the immune response in microglia4. Here, we evaluated the possible role of p53 as a modulator of the microglial response to Aβ25-35, leading to neurodegeneration., Funds: Instituto de Salud Carlos III (PI18/00265;RD16/0019/0018); FEDER; European Union’s Horizon2020 Research and Innovation Programme (GA 686009);Junta de Castilla y León (PhD grant co-financed by Fondo Social Europeo. EDU/601/2020)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Ischemia-induced oxidative stress triggers DNA double strand breaks leading to neuronal apoptosis

  • Alvarez Coruña, Enrique
  • Hermosín Montes, J. M.
  • Mengual, Regina
  • Delgado-Esteban, María
  • Almeida, Angeles
Resumen de la conferencia invitada presentada en el 43rd Annual Meeting of the SEBBM, The maintenance of DNA integrity is essential for neuronal homeostasis. Increased oxidative stress and DNA double strand break (DSB) generation occur in neurological diseases, including neurodegenerative diseases and stroke [1]. However, the interplay between both phenomena and their implication in neuronal death is largely unknown.Here, we aim to investigate the impact of ischemia-induced DNA DSB on neuronal death and the role played by oxidative stress on DNA repair. For this purpose, mouse cortical neuron in primary culture were exposed to an experimental model of ischemia in vitro (oxygen-glucose deprivation, OGD) for 30 minutes followed by 4 hours of reoxygenation [1]. Next, we evaluated DNA DSB generation, protein expression and neuronal apoptosis by using western blot, flow cytometry, and immunostaining. We found that OGD time-dependently increased the expression of the DNA DSB marker, phospho-H2AX [2], which paralleled with a higher expression levels of apoptotic markers, active caspase-3 and p53. Moreover, OGD promoted oxidative stress and neuronal apoptosis, as revealed by the increase in both annexin/7AAD staining and TUNEL assay. Finally, to study the implication of oxidative stress in DNA damage, we used neuronal cultures from embryo mice that constitutively express the catalase in the mitochondria (mCAT), which downmodulates the endogenous generation of reactive oxygen species [3]. We found that mCAT neurons were more resistant to OGD-induced DNA damage and neuronal apoptosis than wild type neurons. Our results demonstrate that oxidative stress might play an important role in DNA DSB generation, which is involved in neuronal apoptosis caused by ischemia., SCIII: PI18/00103;PI18/00285;RD16/0019/0018; FEDER European regional development fund; JCyL: CSI151P20; CLU201703 P.O.FEDER CyL1420 and EDU/556/2019.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Mitochondrial reactive oxygen species regulate cortical organization in the developing brain

  • Mengual, Regina
  • Rodríguez González, Cristina
  • Bobo-Jimenez, Veronica
  • Delgado-Esteban, María
  • Almeida, Angeles
Poster del trabajo presentado en el 43rd Annual Meeting of the Spanish Society of Biochemistry & Molecular Biology, celebrado en Barcelona, del 19 al 22 de julio de 2021, Reactive oxygen species (ROS) participate as second messengers in different signaling pathways.Then, ROS levels regulation is essential to maintain cell physiological processes and homeostasis. In the central nervous system, ROS play key roles in cell proliferation, neuronal differentiation, and synapse maintenance (1). Moreover, mitochondrial ROS (mROS) generated by astrocytes regulate brain metabolism and behavior in the adult. Specifically, the reduction of astrocytic mROS alters neuronal structure and integrity and causes cognitive impairment (2). However, the impact of mROS generation during brain development is unknown, SCIII :PI18/00265-PI18/00103-RD16/0019/0018-FEDER European regional development fund- JCyL:IES007P17-CLU201703- P.O FEDER CyL1420 and EDU/556/2019.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

P53 depletion promotes neovascularization and brain repair after intracerebral hemorrhage

  • Rodríguez González, Cristina
  • Carabias-Carrasco, Mónica
  • Resch-Beusher, Monica
  • Prieto, Estefanía
  • Almeida, Angeles
Resumen del trabajo presentado en el 19 Congreso Nacional de la SENC celebrado en Lleida del 3 al 5 de noviembre de 2021, Brain neovascularization has been associated with good prognosis of intracerebral hemorrhage (ICH) patients. We previously showed that the human Tp53 Arg72Pro SNP modulates brain endothelial cells survival after ICH, which is essential for the secretion of growth factors and cytokines (i.e. VEGF) that mediate the mobilization of endothelial progenitor cells (EPCs) from the bone marrow to the peripheral blood. EPCs promote brain vascular repair after ICH. Then, pro-apoptotic p53 would be a negative regulator of EPC mobilization, thus affecting the functional outcome after ICH. Since p53 is accumulated in the brain after ICH, we speculate that p53 destabilization not only will promote cell survival, but also vascular recovery and brain repair. p53 KO mice were subjected to an experimental model of ICH in vivo by injecting bacterial collagenase into the basal ganglia. Proliferative markers (BrdU, Ki67) and perfusion status of newly-formed blood vessels in the brain was also analyzed after Evans blue injection. We observed that p53 loss reduced lesion volume and significantly boost levels of circulating EPCs in mice from 72 hours after ICH. Knockdown of p53 also increased proliferative events in SVZ and lesion areas, as evidenced by BrdU incorporation and Ki67 staining. Consequently, an improved vascular repair response was achieved in p53 KO mice, in comparison with those expressing an active p53 protein. Our results point out the impact of the p53 signaling pathway in the balance between brain damage and repair, which might condition functional recovery after ICH., Funded by ISCIII (PI18/00265; RD16/0019/0018), FEDER, EU Horizon 2020 Research and Innovation Programme (Grant Agreement 686009), Junta de Castilla y León (CSI151P20; Escalera de Excelencia CLU-2017-03 Cofinanciado por el P.O. FEDER de Castilla y León 14-20); RedHYPOX (SAF2017‐90794‐REDT)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Abrogating mitochondrial ROS in neurons or astrocytes reveals cell-specific impact on mouse behaviour

  • Vicente-Gutiérrez, Carlos
  • Bonora, Nicoló
  • Jimenez-Blasco, Daniel
  • López-Fabuel, Irene
  • Bates, Georgina
  • Murphy, Michael P.
  • Almeida, Angeles
Cells naturally produce mitochondrial reactive oxygen species (mROS), but the in vivo pathophysiological significance has long remained controversial. Within the brain, astrocyte-derived mROS physiologically regulate behaviour and are produced at one order of magnitude faster than in neurons. However, whether neuronal mROS abundance differentially impacts on behaviour is unknown. To address this, we engineered genetically modified mice to down modulate mROS levels in neurons in vivo. Whilst no alterations in motor coordination were observed by down modulating mROS in neurons under healthy conditions, it prevented the motor discoordination caused by the pro-oxidant neurotoxin, 3-nitropropionic acid (3-NP). In contrast, abrogation of mROS in astrocytes showed no beneficial effect against the 3-NP insult. These data indicate that the impact of modifying mROS production on mouse behaviour critically depends on the specific cell-type where they are generated., J.P.B. is funded by the Agencia Estatal de Investigación (SAF2016-78114-R, PID2019-105699RB-I00/AEI/10.13039/501100011033 and RED2018-102576-T), Plan Nacional sobre Drogas (2020I028), ISCIII (CB16/10/00282), Junta de Castilla y Le ́on (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundaci ́on BBVA and Fundaci ́on Ram ́on Areces. A.A. is funded by the ISCIII (PI18/00265, RD16/0019/0018), AEI (SAF2017-90794-REDT) and European Union’s Horizon 2020 Research and Innovation Program (Grant Agreement 686009). J.P.B. and A.A. are funded by the grant CSI151P20 from the Junta de Castilla y Leon.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mitochondrial–nuclear p53 trafficking controls neuronal susceptibility in stroke

  • Almeida, Angeles
  • Sánchez Morán, Irene
  • Rodríguez González, Cristina
Stroke is a major cause of death and long-term disability in the adult. Neuronal apoptosis plays an essential role in the pathophysiology of ischemic brain damage and impaired functional recovery after stroke. The tumor suppressor protein p53 regulates key cellular processes, including cell cycle arrest, DNA repair, senescence, and apoptosis. Under cellular stress conditions, p53 undergoes post-translational modifications, which control protein localization, stability, and proapoptotic activity. After stroke, p53 rapidly accumulates in the ischemic brain, where it activates neuronal apoptosis through both transcriptional-dependent and -independent programs. Over the last years, subcellular localization of p53 has emerged as an important regulator of ischemia-induced neuronal apoptosis. Upon an ischemic insult, p53 rapidly translocates to the mitochondria and interacts with B-cell lymphoma-2 family proteins, which activate the mitochondrial apoptotic program, with higher efficacy than through its activity as a transcription factor. Moreover, the identification of a human single nucleotide polymorphism at codon 72 of the Tp53 gene that controls p53 mitochondrial localization and cell susceptibility to apoptosis supports the important role of the p53 mitochondrial program in neuronal survival and functional recovery after stroke. In this article, we review the relevance of mitochondrial and nuclear localization of p53 on neuronal susceptibility to cerebral ischemia and its impact on functional outcome of stroke patients., Consejería de Educación, Junta de Castilla y León, Grant/Award Numbers: CLU-2017-03, CSI151P20; EU Horizon 2020Research and Innovation Programme,Grant/Award Number: GA 686009;Ministerio de Ciencia e Innovación,Grant/Award Number:SAF2017-90794-REDT to AA; Junta deCastilla y León; Horizon 2020; EuropeanUnion; European Regional DevelopmentFund; Instituto de Salud Carlos III, Grant/Award Numbers: PI18/00265,RD16/0019/0018
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Preclinical Characterization of Antioxidant Quinolyl Nitrone QN23 as a New Candidate for the Treatment of Ischemic Stroke

  • Martínez-Alonso, Emma
  • Escobar-Peso, Alejandro
  • Aliena-Valero, Alicia
  • Torregrosa, Germán
  • Chioua, Mourad
  • Fernández-Serra, Rocío
  • González-Nieto, Daniel
  • Ouahid, Youness
  • Salom, Juan B.
  • Masjuán, Jaime
  • Marco-Contelles, José
  • Alcázar, Alberto
Nitrones are encouraging drug candidates for the treatment of oxidative stress-driven diseases such as acute ischemic stroke (AIS). In a previous study, we found a promising quinolylnitrone, QN23, which exerted a neuroprotective effect in neuronal cell cultures subjected to oxygen–glucose deprivation and in experimental models of cerebral ischemia. In this paper, we update the biological and pharmacological characterization of QN23. We describe the suitability of intravenous administration of QN23 to induce neuroprotection in transitory four-vessel occlusion (4VO) and middle cerebral artery occlusion (tMCAO) experimental models of brain ischemia by assessing neuronal death, apoptosis induction, and infarct area, as well as neurofunctional outcomes. QN23 significantly decreased the neuronal death and apoptosis induced by the ischemic episode in a dose-dependent manner and showed a therapeutic effect when administered up to 3 h after post-ischemic reperfusion onset, effects that remained 11 weeks after the ischemic episode. In addition, QN23 significantly reduced infarct volume, thus recovering the motor function in a tMCAO model. Remarkably, we assessed the antioxidant activity of QN23 in vivo using dihydroethidium as a molecular probe for radical species. Finally, we describe QN23 pharmacokinetic parameters. All these results pointing to QN23 as an interesting and promising preclinical candidate for the treatment of AIS., This work was supported by the Instituto de Salud Carlos III and co-financed by the European Development Regional Fund (FEDER) through grants PI18/00255, RD16/0019/0006, and RD21/0006/0019 to J.M. and A.A., and RD16/0019/0008 and RD21/0006/0014 to J.B.S.; the MINECO grant SAF2015-65586-R to J.M.-C.; and the Comunidad de Madrid Neurocentro project B2017/BMD-3760 to D.G.-N.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke

  • Simats, Alba
  • Ramiro Pascual, Laura
  • Valls, Raquel
  • Ramón, Helena de
  • García-Rodríguez, Paula
  • Orset, Cyrille
  • Artigas, Laura
  • Sardon, Teresa
  • Rosell, Anna
  • Montaner, Joan
Ischemic stroke is a primary cause of morbidity and mortality worldwide. Beyond the approved thrombolytic therapies, there is no effective treatment to mitigate its progression. Drug repositioning combinational therapies are becoming promising approaches to identify new uses of existing drugs to synergically target multiple disease-response mechanisms underlying complex pathologies. Here, we used a systems biology-based approach based on artificial intelligence and pattern recognition tools to generate in silico mathematical models mimicking the ischemic stroke pathology. Combinational treatments were acquired by screening these models with more than 5 million two-by-two combinations of drugs. A drug combination (CA) formed by ceruletide and alpha-1 antitrypsin showing a predicted value of neuroprotection of 92% was evaluated for their synergic neuroprotective effects in a mouse pre-clinical stroke model. The administration of both drugs in combination was safe and effective in reducing by 39.42% the infarct volume 24 h after cerebral ischemia. This neuroprotection was not observed when drugs were given individually. Importantly, potential incompatibilities of the drug combination with tPA thrombolysis were discarded in vitro and in vivo by using a mouse thromboembolic stroke model with t-PA-induced reperfusion, revealing an improvement in the forepaw strength 72 h after stroke in CA-treated mice. Finally, we identified the predicted mechanisms of action of ceruletide and alpha-1 antitrypsin and we demonstrated that CA modulates EGFR and ANGPT-1 levels in circulation within the acute phase after stroke. In conclusion, we have identified a promising combinational treatment with neuroprotective effects for the treatment of ischemic stroke., Neurovascular Research Laboratory acknowledges funding for this project by PI15/00354 and PI18/00804 grants from Instituto Carlos III; the Spanish neurovascular research network INVICTUS PLUS (RD16/0019/0021) also from the Instituto de Salud Carlos III (co-financed by the European Regional Development Fund, FEDER); the program 2017-SGR-1427 from the Generalitat de Catalunya; and the “Advanced Neuroprotection Repurposing Drugs and Nutraceuticals for Stroke in Andalusia: NARDNIA Project,” and COMBINA2 project both funded by the Andalusian Ministry of Health (PE-0527–2019 and PY20-01351). L.R. is supported by a predoctoral fellowship grant (IFI17/00012), from Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Oxidative stress-triggered nuclear WRAP53 translocation promotes neuronal survival and functional recovery after stroke

  • Sánchez Morán, Irene
  • Rodríguez González, Cristina
  • Bolaños, Juan P.
  • Almeida, Angeles
Trabajo presentado en la 20th Biennial Meeting of The Society for Free Radical Research International (SFRR-I) celebrada online del 15 al 18 de marzo de 2021, Ischemic stroke is the leading cause of neurologic death and long-term adult disability worldwide. Ischemia-induced oxidative stress compromises genome integrity, resulting in DNA damage. Failure of neurons to efficiently repair DNA double-strands breaks (DSB) contributes to cerebral damage and impairs functional recovery after stroke. However, the molecular machinery that regulates DNA repair in this neurological disorder remains unknown. Here we describe that WRAP53 (WD40 encoding RNA Antisense to p53), a scaffold protein implicated in telomere elongation and DNA repair in tumor cells, plays an essential role in neuronal survival after ischemia. We found that experimental ischemia, performed by oxygen and glucose deprivation (OGD), promoted oxidative stress-induced DSB in neurons. These events spatiotemporally correlated with WRAP53 upregulation and nuclear translocation to activate DSBs repair response. Mechanistically, OGD triggered a burst in reactive oxygen species that induced both DSB and translocation of WRAP53 to the nucleus to promote DNA repair, a pathway that was confirmed in an in vivo mouse model of stroke. Noticeably, nuclear translocation of WRAP53 occurred faster in OGD neurons expressing the Wrap53 human nonsynonymous single-nucleotide polymorphism (SNP) rs2287499 (c.202C>G). Patients carrying this SNP showed less infarct volume and better functional outcome after stroke. These results provide a new signaling role for reactive oxygen species in the mechanism of DSB repair in neurons and unravel the role of WRAP53 to maintaining genome integrity and survival after stroke., This work was funded by the Instituto de Salud Carlos III (PI18/00265 and RD16/0019/0018), European Regional Development Fund (FEDER), Ministerio de Ciencia en Innovación (SAF2017-90794-REDT), European Union’s Horizon 2020 Research and Innovation Programme (grant agreement 686009), Junta de Castilla y León (IES007P17 and Escalera de Excelencia CLU-2017-03 Cofinanciado por el P.O. FEDER de Castilla y León), and Fundación Ramón Areces.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial

  • Moniche, Francisco
  • Cabezas, Juan A.
  • Valverde, Roberto
  • Escudero-Martínez, Irene
  • Lebrato, Lucía
  • Pardo‐Galiana, Blanca
  • Ainz-Gómez, Leire
  • Medina-Rodríguez, Manuel
  • Torre, Javier de la
  • Escamilla-Gómez, Virginia
  • Ortega-Quintanilla, Joaquín
  • Zapata‐Arriaza, Elena
  • Albóniga-Chindurza, Asier de
  • Mancha, Fernando
  • Gamero-García, Miguel Ángel
  • Pérez-Sánchez, Soledad
  • Espinosa-Rosso, Raúl
  • Forero-Diaz, Lucía
  • Moya, Miguel Ángel
  • Piñero, Pilar
  • Calderón-Cabrera, Cristina
  • Nogueras, Sonia
  • Jiménez, Rosario
  • Martin, Vanesa
  • Delgado, Fernando
  • Ochoa-Sepúlveda, Juan José
  • Quijano, Blanca
  • Mata, Rosario
  • Santos-González, Mónica
  • Carmona Sánchez, Gloria
  • Herrera, Concha
  • González-García, Alejandro
  • Montaner, Joan
[Background] Pilot clinical trials have shown the safety of intra-arterial bone marrow mononuclear cells (BMMNCs) in stroke. However, the efficacy of different doses of intra-arterial BMMNCs in patients with acute stroke has not been tested in a randomised clinical trial. We aimed to show safety and efficacy of two different doses of autologous intra-arterial BMMNC transplantation in patients with acute stroke., [Methods] The IBIS trial was a multicentre phase 2, randomised, controlled, investigator-initiated, assessor-blinded, clinical trial, in four stroke centres in Spain. We included patients (aged 18–80 years) with a non-lacunar, middle cerebral artery ischaemic stroke within 1–7 days from stroke onset and with a National Institutes of Health Stroke Scale score of 6–20. We randomly assigned patients (2:1:1) with a computer-generated randomisation sequence to standard of care (control group) or intra-arterial injection of autologous BMMNCs at one of two different doses (2 × 106 BMMNCs/kg or 5 × 106 BMMNCs/kg). The primary efficacy outcome was the proportion of patients with modified Rankin Scale scores of 0–2 at 180 days in the intention-to-treat population, comparing each BMMNC dose group and the pooled BMMNC group versus the control group. The primary safety endpoint was the proportion of serious adverse events. This trial was registered at ClinicalTrials.gov, NCT02178657 and is completed., [Findings] Between April 1, 2015, and May 20, 2021, we assessed 114 patients for eligibility. We randomly assigned 77 (68%) patients: 38 (49%) to the control group, 20 (26%) to the low-dose BMMNC group, and 19 (25%) the high-dose BMMNC group. The mean age of participants was 62·4 years (SD 12·7), 46 (60%) were men, 31 (40%) were women, all were White, and 63 (82%) received thrombectomy. The median NIHSS score before randomisation was 12 (IQR 9–15), with intra-arterial BMMNC injection done a median of 6 days (4–7) after stroke onset. The primary efficacy outcome occurred in 14 (39%) patients in the control group versus ten (50%) in the low-dose group (adjusted odds ratio 2·08 [95% CI 0·55–7·85]; p=0·28), eight (44%) in the high-dose group (1·89 [0·52–6·96]; p=0·33), and 18 (47%) in the pooled BMMNC group (2·22 [0·72–6·85]; p=0·16). We found no differences in the proportion of patients who had adverse events or dose-related events, but two patients had a groin haematoma after cell injection in the low-dose BMMNC group., [Interpretation] Intra-arterial BMMNCs were safe in patients with acute ischaemic stroke, but we found no significant improvement at 180 days on the mRS. Further clinical trials are warranted to investigate whether improvements might be possible at different timepoints., The Andalusian Network for the Design and Translation of Advanced Therapies through the Andalusian Progress and Health Public Foundation is the study sponsor. We acknowledge all the participants of the trial and the investigators. We thank the funding bodies Instituto de Salud Carlos III through the projects PI18/01414, PI15/01197, RD16/0019/0015 (INVICTUS+), and RD21/0006/0015 (co-funded by the European Regional Development Fund “A way to make Europe” and by the European Social Fund [FSE] “The FSE invests in your future”), Mutua Madrileña grant, and the Regional Ministry of Health of Andalusia, who financed the costs incurred by participating hospitals and the Andalusian Network for the Design and Translation of Advanced Therapies through the Andalusian Progress and Health Public Foundation. MM-R has a Rio Hortega grant (CM21/00096). We acknowledge the Methodological and Statistical Support Unit from the Andalusian Public Foundation for Health Research Management in Seville (FISEVI) for their support in the statistical analysis., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol

  • Medina-Rodríguez, Manuel
  • Moniche, Francisco
  • Albóniga-Chindurza, Asier de
  • Ortega-Quintanilla, Joaquín
  • Ainz-Gómez, Leire
  • Pardo‐Galiana, Blanca
  • Cabezas, Juan A.
  • Aguilar-Pérez, Marta
  • Zamora, Aynara
  • Delgado-Acosta, Fernando
  • Jiménez-Gómez, Elvira
  • Bravo-Rey, Isabel
  • Oteros-Fernández, Rafael
  • Freijo-Guerrero, Maria del Mar
  • González-Díaz, Eva
  • Escudero-Martínez, Irene
  • Morales-Caba, Lluis
  • Vielba-Gómez, Isabel
  • Mosteiro, Sonia
  • Castellanos-Rodrigo, María del Mar
  • Pascasio, Laura Amaya
  • Hidalgo, Carlos
  • Fernández-Prudencio, Luis
  • Ramírez-Moreno, José M.
  • Díaz-Pérez, José
  • Sanz-Fernández, Gema
  • Baena-Palomino, Pablo
  • Gamero-García, Miguel Ángel
  • Jiménez-Jorge, Silvia
  • Rosso-Fernández, Clara
  • Montaner, Joan
  • González-García, Alejandro
  • Zapata‐Arriaza, Elena
[Background] In-stent thrombosis after mechanical thrombectomy (MT) worsen outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Although an optimal antiplatelet therapy is needed, the best approach to avoid in-stent thrombosis is yet to be elucidated., [Hypothesis] Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL., [Methods] The ATILA-trial is a multicenter, prospective, phase IV, randomized, controlled (aspirin group as control), assessor-blinded clinical trial. Patients fulfilling inclusion criteria (AIS due to TL, ASPECTS ⩾ 6, pre-stroke modified Rankin Scale ⩽2 and onset <24 h) will be randomized (1:1) at MT onset to experimental (intravenous tirofiban) or control group (intravenous aspirin). Intravenous aspirin will be administered at a 500 mg single dose and tirofiban at a 500 µg bolus followed by a 200 µg/h infusion during first 22 h. All patients will be followed up to 3 months. Sample size estimated is 240 patients., [Outcomes] The primary efficacy outcome is the proportion of patients with carotid in-stent thrombosis within the first 24 h after MT. The primary safety outcome is the rate of symptomatic intracranial hemorrhage. Secondary outcomes include functional independence defined as modified Rankin Scale 0–2, proportion of patients undergoing rescue therapy due to in-stent aggregation during MT and carotid reocclusion at 30 days., [Discussion] ATILA-trial will be the first clinical trial regarding the best antiplatelet therapy to avoid in-stent thrombosis after MT in patients with TL., [Trial registration] NCT0522596., This project was funded by the Instituto de Salud Carlos III (ISCIII) through the project PI21/01322 and co-funded by the European Union. The Spanish Clinical Research Network (SCReN-Code:21.033) also contributed to the study. The ITRIBiS project (Improving Translational Research Potential at the Institute of Biomedicine of Seville) has the registration number REGPOT-2013-1. M. Medina-Rodríguez was granted a Rio Hortega contract (CM21/00096). The project was included in the Cooperative Cerebrovascular Disease Research Network (INVICTUS) (RD16/0019/0015)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Oral Anticoagulation and Risk of Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Mechanical Thrombectomy: Data From the Nordictus Registry

  • Ramos-Araque, M.E.
  • Chavarría-Miranda, A.
  • Gómez-Vicente, B.
  • López-Cancio Martínez, E.
  • Castañón Apilánez, M.
  • Castellanos, M.
  • López Fernández, M.
  • Tejada Meza, H.
  • Marta Moreno, J.
  • Tejada García, J.
  • Beltrán Rodríguez, I.
  • de la Riva, P.
  • Díez, N.
  • Arias Rivas, S.
  • Santamaría Cadavid, M.
  • Bravo Anguiano, Y.
  • Bártulos Iglesias, M.
  • Palacio Portilla, E.J.
  • Revilla García, M.
  • Timiraos Fernández, J.J.
  • Arenaza Basterrechea, N.
  • Maciñeiras Montero, J.L.
  • Vicente Alba, P.
  • Julián Villaverde, F.J.
  • Pinedo Brochado, A.
  • Azkune, I.
  • Mar, F.M.
  • Luna, A.
  • Arenillas, J.F.
Introduction: We aimed to evaluate if prior oral anticoagulation (OAC) and its type determines a greater risk of symptomatic hemorrhagic transformation in patients with acute ischemic stroke (AIS) subjected to mechanical thrombectomy. Materials and Methods: Consecutive patients with AIS included in the prospective reperfusion registry NORDICTUS, a network of tertiary stroke centers in Northern Spain, from January 2017 to December 2019 were included. Prior use of oral anticoagulants, baseline variables, and international normalized ratio (INR) on admission were recorded. Symptomatic intracranial hemorrhage (sICH) was the primary outcome measure. Secondary outcome was the relation between INR and sICH, and we evaluated mortality and functional outcome at 3 months by modified Rankin scale. We compared patients with and without previous OAC and also considered the type of oral anticoagulants. Results: About 1.455 AIS patients were included, of whom 274 (19%) were on OAC, 193 (70%) on vitamin K antagonists (VKA), and 81 (30%) on direct oral anticoagulants (DOACs). Anticoagulated patients were older and had more comorbidities. Eighty-one (5.6%) developed sICH, which was more frequent in the VKA group, but not in DOAC group. OAC with VKA emerged as a predictor of sICH in a multivariate regression model (OR, 1.89 [95% CI, 1.01–3.51], p = 0.04) and was not related to INR level on admission. Prior VKA use was not associated with worse outcome in the multivariate regression model nor with mortality at 3 months. Conclusions: OAC with VKA, but not with DOACs, was an independent predictor of sICH after mechanical thrombectomy. This excess risk was associated neither with INR value by the time thrombectomy was performed, nor with a worse functional outcome or mortality at 3 months.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Functional Recovery and Serum Angiogenin Changes According to Intensity of Rehabilitation Therapy After Stroke

  • Garcia Rodriguez, Nicolas
  • Rodriguez Gonzalez, Susana
  • Ignacio Tejada, Pedro
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez Bazan, Laura Mónica
  • Quintana Luque, Manuel
  • Olive Gadea, Marta
  • Penalba Morenilla, Anna
  • Rosell Novel, Anna
  • Inzitari, Marco
  • Perez-Mesquida, Maria Engracia
Angiogenina; Terapia intensiva; Rehabilitación, Angiogenin; Intensive therapy; Rehabilitation, Angiogenina; Teràpia intensiva; Rehabilitació, Background: Rehabilitation is still the only treatment available to improve functional status after the acute phase of stroke. Most clinical guidelines highlight the need to design rehabilitation treatments considering starting time, intensity, and frequency, according to the tolerance of the patient. However, there are no homogeneous protocols and the biological effects are under investigation. Objective: To investigate the impact of rehabilitation intensity (hours) after stroke on functional improvement and serum angiogenin (ANG) in a 6-month follow-up study. Methods: A prospective, observational, longitudinal, and multicenter study with three cohorts: strokes in intensive rehabilitation therapy (IRT, minimum 15 h/week) vs. conventional therapy (NO-IRT, <15 h/week), and controls subjects (without known neurological, malignant, or inflammatory diseases). A total of seven centers participated, with functional evaluations and blood sampling during follow-up. The final cohort includes 62 strokes and 43 controls with demographic, clinical, blood samples, and exhaustive functional monitoring. Results: The median (IQR) number of weekly hours of therapy was different: IRT 15 (15–16) vs. NO-IRT 7.5 (5–9), p < 0.01, with progressive and significant improvements in both groups. However, IRT patients showed earlier improvements (within 1 month) on several scales (CAHAI, FMA, and FAC; p < 0.001) and the earliest community ambulation achievements (0.89 m/s at 3 months). There was a significant difference in ANG temporal profile between the IRT and NO-IRT groups (p < 0.01). Additionally, ANG was elevated at 1 month only in the IRT group (p < 0.05) whereas it decreased in the NO-IRT group (p < 0.05). Conclusions: Our results suggest an association of rehabilitation intensity with early functional improvements, and connect the rehabilitation process with blood biomarkers., NG-R holds a VHIR fellowship and MO-G a Joan Margarit VHIR fellowship. Research grants: from the Instituto de Salud Carlos III and European Regional Development Funds (PI16/00981, PI19/00186, RD16/0019/0021, and RD16/0019/0008), 2017-SGR-1427 program from the Generalitat de Catalunya-AGAUR, and Clinical Translational Program for Regenerative Medicine in Catalonia (P-CMR [C]).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Angiogenin in the Neurogenic Subventricular Zone After Stroke

  • Gabriel Salazar, Marina
  • Lei (Santiago), Ting
  • Grayston Morales, Alba
  • Costa Riu, Carme
  • Medina Gutierrez, Esperanza
  • Montaner Villalonga, Joan
  • Rosell Novel, Anna
  • Comabella Lopez, Manuel
Angiogenina; Exercici; Neuroreparació, Angiogenina; Ejercicio; Neuroreparación, Angiogenin; Exercise; Neurorepair, Ischemic stroke is a leading cause of death and disability worldwide with effective acute thrombolytic treatments. However, brain repair mechanisms related to spontaneous or rehabilitation-induced recovery are still under investigation, and little is known about the molecules involved. The present study examines the potential role of angiogenin (ANG), a known regulator of cell function and metabolism linked to neurological disorders, focusing in the neurogenic subventricular zone (SVZ). Angiogenin expression was examined in the mouse SVZ and in SVZ-derived neural stem cells (NSCs), which were exposed to exogenous ANG treatment during neurosphere formation as well as in other neuron-like cells (SH-SY5Y). Additionally, male C57Bl/6 mice underwent a distal permanent occlusion of the middle cerebral artery to study endogenous and exercise-induced expression of SVZ-ANG and neuroblast migration. Our results show that SVZ areas are rich in ANG, primarily expressed in DCX+ neuroblasts but not in nestin+NSCs. In vitro, treatment with ANG increased the number of SVZ-derived NSCs forming neurospheres but could not modify SH-SY5Y neurite differentiation. Finally, physical exercise rapidly increased the amount of endogenous ANG in the ipsilateral SVZ niche after ischemia, where DCX-migrating cells increased as part of the post-stroke neurogenesis process. Our findings position for the first time ANG in the SVZ during post-stroke recovery, which could be linked to neurogenesis., MG-S was supported by a pre-doctoral fellowship from the Vall d'Hebron Research Institute, AR was supported by the Miguel Servet program and AG holds a pre-doctoral fellowship both from Instituto Carlos III (CPII15/00003 and FI17/00073, respectively), and TL was supported by the China Scholarship Council (CSC-201706170048). This research has been funded by grants PI16/00981, PI19/00186, and RD16/0019/0021 (RETICS-INVICTUS PLUS) from the Instituto de Salud Carlos III co-financed by the European Regional Development Funds, and by the Generalitat de Catalunya (2017SGR 1427).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease

  • Camacho Soriano, Jessica
  • Rábano, Alberto
  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Serna Alonso, Garazi
  • Moline Marimon, Teresa
  • Ramon y Cajal Agüeras, Santiago
  • Martinez Saez, Elena Antima
  • Hernandez Guillamon, Maria Mar
Alzheimer; CD2AP; Enfermedad de Pick, Alzheimer's disease; CD2AP; Pick's disease, Alzheimer; CD2AP; Malaltia de Pick, Genome-wide association studies have described several genes as genetic susceptibility loci for Alzheimer's disease (AD). Among them, CD2AP encodes CD2-associated protein, a scaffold protein implicated in dynamic actin remodeling and membrane trafficking during endocytosis and cytokinesis. Although a clear link between CD2AP defects and glomerular pathology has been described, little is known about the function of CD2AP in the brain. The aim of this study was to analyze the distribution of CD2AP in the AD brain and its potential associations with tau aggregation and β-amyloid (Aβ) deposition. First, we performed immunohistochemical analysis of CD2AP expression in brain tissue from AD patients and controls (N = 60). Our results showed granular CD2AP immunoreactivity in the human brain endothelium in all samples. In AD cases, no CD2AP was found to be associated with Aβ deposits in vessels or parenchymal plaques. CD2AP neuronal inclusions similar to neurofibrillary tangles (NFT) and neuropil thread-like deposits were found only in AD samples. Moreover, immunofluorescence analysis revealed that CD2AP colocalized with pTau. Regarding CD2AP neuronal distribution, a hierarchical progression from the entorhinal to the temporal and occipital cortex was detected. We found that CD2AP immunodetection in neurons was strongly and positively associated with Braak neurofibrillary stage, independent of age and other pathological hallmarks. To further investigate the association between pTau and CD2AP, we included samples from cases of primary tauopathies (corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], and Pick's disease [PiD]) in our study. Among these cases, CD2AP positivity was only found in PiD samples as neurofibrillary tangle-like and Pick body-like deposits, whereas no neuronal CD2AP deposits were detected in PSP or CBD samples, which suggested an association of CD2AP neuronal expression with 3R-Tau-diseases. In conclusion, our findings open a new road to investigate the complex cellular mechanism underlying the tangle conformation and tau pathology in the brain., This work was funded by Instituto de Salud Carlos III (ISCIII) (PI17/00275, PI20/00465), cofinanced by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. is supported by the Miguel Servet Programme, ISCIII, Spain (CPII17/00010)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Blood flow response to orthostatic challenge identifies signatures of the failure of static cerebral autoregulation in patients with cerebrovascular disease

  • Gregori-Pla, Clara
  • Mesquita, Rickson C.
  • Favilla, Christopher G.
  • Busch, David R.
  • Blanco, Igor
  • Zirak, Peyman
  • Maruccia, Federica
Autorregulació cerebral; Malaltia cerebrovascular; Òptica difusa, Autorregulación cerebral; Enfermedad cerebrovascular; Óptica difusa, Cerebral autoregulation; Cerebrovascular disease; Diffuse optics, Background The cortical microvascular cerebral blood flow response (CBF) to different changes in head-of-bed (HOB) position has been shown to be altered in acute ischemic stroke (AIS) by diffuse correlation spectroscopy (DCS) technique. However, the relationship between these relative ΔCBF changes and associated systemic blood pressure changes has not been studied, even though blood pressure is a major driver of cerebral blood flow. Methods Transcranial DCS data from four studies measuring bilateral frontal microvascular cerebral blood flow in healthy controls (n = 15), patients with asymptomatic severe internal carotid artery stenosis (ICA, n = 27), and patients with acute ischemic stroke (AIS, n = 72) were aggregated. DCS-measured CBF was measured in response to a short head-of-bed (HOB) position manipulation protocol (supine/elevated/supine, 5 min at each position). In a sub-group (AIS, n = 26; ICA, n = 14; control, n = 15), mean arterial pressure (MAP) was measured dynamically during the protocol. Results After elevated positioning, DCS CBF returned to baseline supine values in controls (p = 0.890) but not in patients with AIS (9.6% [6.0,13.3], mean 95% CI, p < 0.001) or ICA stenosis (8.6% [3.1,14.0], p = 0.003)). MAP in AIS patients did not return to baseline values (2.6 mmHg [0.5, 4.7], p = 0.018), but in ICA stenosis patients and controls did. Instead ipsilesional but not contralesional CBF was correlated with MAP (AIS 6.0%/mmHg [− 2.4,14.3], p = 0.038; ICA stenosis 11.0%/mmHg [2.4,19.5], p < 0.001). Conclusions The observed associations between ipsilateral CBF and MAP suggest that short HOB position changes may elicit deficits in cerebral autoregulation in cerebrovascular disorders. Additional research is required to further characterize this phenomenon., The funders did not have any role in study design, execution and data interpretation. This work was funded by Redes Temáticas de Investigación Cooperativa (RETICS-INVICTUS RD012/0014 and RD16/0019/0010), Fundació CELLEX Barcelona, Ministerio de Economía y Competitividad/FEDER (PHOTODEMENTIA, PHOTOMETABO, DPI2015–64358-C2–1-R, PRE2018-085082), Instituto de Salud Carlos III/FEDER (FIS PI09/0557, MEDPHOTAGE, DTS16/00087), the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2015-0522), the Obra Social “la Caixa” Foundation (LlumMedBcn), Institució “Centres de Recerca de Catalunya”, “Agència de Gestió d’Ajuts Universitaris i de Recerca”-Generalitat (2017SGR-1380), LASERLAB-EUROPE IV (EU-H2020 654148), Whitaker International Program of the Institute for International Education, T32 HL007954 Multidisciplinary training in cardiovascular biology, Marie Curie initial training network (OILTEBIA 317526), Marie Sklowdowska-Curie-COFUND (H2020, ICFOstepstone 2, 71329), “Fundació La Marató TV3” (201709.30, 201709.31), São Paulo Research Foundation (FAPESP) through 2012/02500–8 and National Institutes of Health (R01-NS060653, K24-NS058386, R24-HD050836, P41-EB015893, DP2-HD101400, U54-HD086984).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

  • Bonaterra Pastra, Anna
  • Fernández de Retana, Sofía
  • Rivas-Urbina, Andrea
  • Puig, Núria
  • Benítez, Sònia
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Apolipoproteïnes; Angiopatia amiloide cerebral, Enfermedad de Alzheimer; Apolipoproteínas; Angiopatía amiloide cerebral, Alzheimer’s disease; Apolipoproteins; Cerebral amyloid angiopathy, Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation., This research was funded by Instituto de Salud Carlos III (co-financed by the European Regional Development Fund FEDER “Una manera de hacer Europa”), grant numbers PI13/00364, PI16/00471, PI14/01134 and PI17/00275. A.R.-U. was funded by Instituto de Salud Carlos III predoctoral contract FI17/00031. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain [RD16/0019/0021]. J.L.S.-Q. is a member of the CIBER of Diabetes and Metabolism (CIBERDEM), ISCIII, Spain. M.H.-G. is supported by the Miguel Servet programme, ISCIII, Spain [CPII17/00010]. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Quality Research Group 2017-SGR-1149 from Generalitat de Catalunya. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Group of Vascular Biology from the Spanish Atherosclerosis Society.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

  • Marazuela Fuentes, Paula
  • Solé Piñol, Montserrat
  • Bonaterra Pastra, Anna
  • Pizarro Gonzálvez, Jesús
  • Camacho Soriano, Jessica
  • Martinez Saez, Elena Antima
  • Castillo Ribelles, Laura
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Biomarcadors; Microdissecció de captura làser, Alzheimer's disease; Biomarkers; Laser capture microdissection, Enfermedad de Alzheimer; Biomarcadores; Microdisección por captura láser, Brain accumulation of amyloid-beta (Aβ) is a crucial feature in Alzheimer´s disease (AD) and cerebral amyloid angiopathy (CAA), although the pathophysiological relationship between these diseases remains unclear. Numerous proteins are associated with Aβ deposited in parenchymal plaques and/or cerebral vessels. We hypothesized that the study of these proteins would increase our understanding of the overlap and biological differences between these two pathologies and may yield new diagnostic tools and specific therapeutic targets. We used a laser capture microdissection approach combined with mass spectrometry in the APP23 transgenic mouse model of cerebral-β-amyloidosis to specifically identify vascular Aβ-associated proteins. We focused on one of the main proteins detected in the Aβ-affected cerebrovasculature: MFG-E8 (milk fat globule-EGF factor 8), also known as lactadherin. We first validated the presence of MFG-E8 in mouse and human brains. Immunofluorescence and immunoblotting studies revealed that MFG-E8 brain levels were higher in APP23 mice than in WT mice. Furthermore, MFG-E8 was strongly detected in Aβ-positive vessels in human postmortem CAA brains, whereas MFG-E8 was not present in parenchymal Aβ deposits. Levels of MFG-E8 were additionally analysed in serum and cerebrospinal fluid (CSF) from patients diagnosed with CAA, patients with AD and control subjects. Whereas no differences were found in MFG-E8 serum levels between groups, MFG-E8 concentration was significantly lower in the CSF of CAA patients compared to controls and AD patients. Finally, in human vascular smooth muscle cells MFG-E8 was protective against the toxic effects of the treatment with the Aβ40 peptide containing the Dutch mutation. In summary, our study shows that MFG-E8 is highly associated with CAA pathology and highlights MFG-E8 as a new CSF biomarker that could potentially be used to differentiate cerebrovascular Aβ pathology from parenchymal Aβ deposition., This work was funded by the Instituto de Salud Carlos III (ISCIII), (PI20/00465), co-financed by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS + network, ISCIII, Spain (RD16/0019/0021). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute. MMV is supported by the BIONIC project (no. 733050822, which has been made possible by ZonMW as part of ‘Memorabel’, the research and innovation program for dementia, as part of the Dutch national ‘Deltaplan for Dementia’:the CAFÉ project (the National Institutes of Health, USA, grant number 5R01NS104147-02), and a grant from the Selfridges Group Foundation (NR170024). The BIONIC project is a consortium of Radboudumc, LUMC, ADX Neurosciences, and Rhode Island University.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke

  • Ramiro Pascual, Laura
  • Quintana Luque, Manuel
  • Garcia Rodriguez, Paula
  • Santamarina Pérez, Estevo
  • Alvarez Sabin, José
  • Bustamante Rangel, Alejandro
  • Montaner Villalonga, Joan
  • Abraira del Fresno, Laura
Biomarcador; Endostatina; Accident cerebrovascular isquèmic, Biomarcador; Endostatina; Accidente cerebrovascular isquémico, Biomarker; Endostatin; Ischemic stroke, Stroke is a major cause of disability and death globally, and prediction of mortality represents a crucial challenge. We aimed to identify blood biomarkers measured during acute ischemic stroke that could predict long-term mortality. Nine hundred and forty-one ischemic stroke patients were prospectively recruited in the Stroke-Chip study. Post-stroke mortality was evaluated during a median 4.8-year follow-up. A 14-biomarker panel was analyzed by immunoassays in blood samples obtained at hospital admission. Biomarkers were normalized and standardized using Z-scores. Multiple Cox regression models were used to identify clinical variables and biomarkers independently associated with long-term mortality and mortality due to stroke. In the multivariate analysis, the independent predictors of long-term mortality were age, female sex, hypertension, glycemia, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Independent blood biomarkers predictive of long-term mortality were endostatin > quartile 2, tumor necrosis factor receptor-1 (TNF-R1) > quartile 2, and interleukin (IL)-6 > quartile 2. The risk of mortality when these three biomarkers were combined increased up to 69%. The addition of the biomarkers to clinical predictors improved the discrimination (integrative discriminative improvement (IDI) 0.022 (0.007–0.048), p < 0.001). Moreover, endostatin > quartile 3 was an independent predictor of mortality due to stroke. Altogether, endostatin, TNF-R1, and IL-6 circulating levels may aid in long-term mortality prediction after stroke., This work has been funded by Instituto de Salud Carlos III (PI18/00804) and by La Fundació La Marató (Reg. 84/240 proj. 201702). Neurovascular Research Laboratory takes part in the Spanish stroke research network INVICTUS+ (RD16/0019/0021). L.R. is supported by a pre-doctoral fellowship from the Instituto de Salud Carlos III (IFI17/00012).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Survival Bias and Crosstalk between Chronological and Behavioral Age: Age- and Genotype-Sensitivity Tests Define Behavioral Signatures in Middle-Aged, Old, and Long-Lived Mice with Normal and AD-Associated Aging

  • Marin-Pardo, Daniela
  • Marazuela Fuentes, Paula
  • Hernandez Guillamon, Maria Mar
  • Giménez-Llort, Lydia
Malaltia d'Alzheimer; Envelliment; Supervivència, Alzheimer’s disease; Aging; Survival, Enfermedad de Alzheimer; Envejecimiento; Supervivencia, New evidence refers to a high degree of heterogeneity in normal but also Alzheimer’s disease (AD) clinical and temporal patterns, increased mortality, and the need to find specific end-of-life prognosticators. This heterogeneity is scarcely explored in very old male AD mice models due to their reduced survival. In the present work, using 915 (432 APP23 and 483 C57BL/6 littermates) mice, we confirmed the better survival curves in male than female APP23 mice and respective wildtypes, providing the chance to characterize behavioral signatures in middle-aged, old, and long-lived male animals. The sensitivity of a battery of seven paradigms for comprehensive screening of motor (activity and gait analysis), neuropsychiatric and cognitive symptoms was analyzed using a cohort of 56 animals, composed of 12-, 18- and 24-month-old male APP23 mice and wildtype littermates. Most variables analyzed detected age-related differences. However, variables related to coping with stress, thigmotaxis, frailty, gait, and poor cognition better discriminated the behavioral phenotype of male APP23 mice through the three old ages compared with controls. Most importantly, non-linear age- and genotype-dependent behavioral signatures were found in long-lived animals, suggesting crosstalk between chronological and biological/behavioral ages useful to study underlying mechanisms and distinct compensations through physiological and AD-associated aging., This work was funded by the BrightFocus Foundation, US (A2017243S). The Neurovascular Research Laboratory is part of the INVICTUS+network, Instituto de Salud Carlos III (ISCIII), Spain [RD16/0019/0021], co-financed by the European Regional Development Fund FEDER. P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer’s Disease

  • Unzeta, Mercedes
  • Hernandez Guillamon, Maria Mar
  • Sun, Ping
  • Solé Piñol, Montserrat
Alzheimer’s disease; Inflammation; Vascular damage, Malaltia d'Alzheimer; Inflamació; Lesions vasculars, Enfermedad de Alzheimer; Inflamación; Lesión vascular, The semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1) or primary amine oxidase (PrAO), is a deaminating enzyme highly expressed in vessels that generates harmful products as a result of its enzymatic activity. As a multifunctional enzyme, it is also involved in inflammation through its ability to bind and promote the transmigration of circulating leukocytes into inflamed tissues. Inflammation is present in different systemic and cerebral diseases, including stroke and Alzheimer’s disease (AD). These pathologies show important affectations on cerebral vessels, together with increased SSAO levels. This review summarizes the main roles of SSAO/VAP-1 in human physiology and pathophysiology and discusses the mechanisms by which it can affect the onset and progression of both stroke and AD. As there is an evident interrelationship between stroke and AD, basically through the vascular system dysfunction, the possibility that SSAO/VAP-1 could be involved in the transition between these two pathologies is suggested. Hence, its inhibition is proposed to be an interesting therapeutical approach to the brain damage induced in these both cerebral pathologies., This research received no external funding. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Reverté, Silvia
  • Garcia Berrocoso, Teresa
  • Millán Torné, Mònica
  • Castellanos, Mar
  • Ventura Ripoll, Oriol
  • Rubiera Del Fueyo, Marta Aurora
  • Montaner Villalonga, Joan
Biomarkers; Stroke; Stroke‐associated infection, Biomarcadors; Ictus; Infecció associada a un ictus, Biomarcadores; Ictus; Infección asociada a un ictus, Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life‐threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty‐eight patients experiencing ischemic stroke were prospectively recruited in the Stroke‐Chip study. Post‐stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log‐transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10‐fold cross‐validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three‐biomarker panels were developed as predictors: vascular adhesion protein‐1 >5.67, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) >4.98 and d‐dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin‐6 >3.97, von Willebrand factor >3.67, and d‐dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3–52.2]; panel for RTI: OR, 3.73 [1.95–7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea., This project received funding from Instituto de Salud Carlos III (ISCIII) [DTS14/00004, PI17/02130], co‐financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706] and the European Union's Horizon 2020 research and innovation program [754517]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ (RD16/0019/0021). The funders had no role in the study design and conduction.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization

  • Aliena-Valero, Alicia
  • Hernández Jiménez, Macarena
  • López Morales, Mikahela
  • Tamayo-Torres, Eva
  • Castelló-Ruiz, Maria
  • Piñeiro, David
  • Ribo, Marc
Aptamers; Cerebroprotection; Ischemic stroke, Aptàmers; Cerebroprotecció; Ictus isquèmic, Aptámeros; Cerebroprotección; Ictus isquémico, ApTOLL, a TLR4 modulator aptamer, has demonstrated cerebroprotective effects in a permanent ischemic stroke mouse model, as well as safety and efficacy in early phase clinical trials. We carried out reverse translation research according to STAIR recommendations to further characterize the effects and mechanisms of ApTOLL after transient ischemic stroke in rats and to better inform the design of pivotal clinical trials. Adult male rats subjected to transient middle cerebral artery occlusion were treated either with ApTOLL or the vehicle intravenously at different doses and time-points. ApTOLL was compared with TAK-242 (a TLR4 inhibitor). Female rats were also studied. After neurofunctional evaluation, brains were removed for infarct/edema volume, hemorrhagic transformation, and histologic determinations. Peripheral leukocyte populations were assessed via flow cytometry. ApTOLL showed U-shaped dose-dependent cerebroprotective effects. The maximum effective dose (0.45 mg/kg) was cerebroprotective when given both before reperfusion and up to 12 h after reperfusion and reduced the hemorrhagic risk. Similar effects occurred in female rats. Both research and clinical ApTOLL batches induced slightly superior cerebroprotection when compared with TAK-242. Finally, ApTOLL modulated circulating leukocyte levels, reached the brain ischemic tissue to bind resident and infiltrated cell types, and reduced the neutrophil density. These results show the cerebroprotective effects of ApTOLL in ischemic stroke by reducing the infarct/edema volume, neurofunctional impairment, and hemorrhagic risk, as well as the peripheral and local immune response. They provide information about ApTOLL dose effects and its therapeutic time window and target population, as well as its mode of action, which should be considered in the design of pivotal clinical trials., This study was sponsored by AptaTargets S.L. (Madrid, Spain) and co-funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTC-2019-006795-1), Centro para el Desarrollo Tecnológico Industrial (IDI-20210746), and Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”) (RD16/0019/0008 and RD21/0006/0014). The funders were not involved in the study design; collection, analysis, or interpretation of data; the writing of this article; or the decision to submit it for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Stroke-induced immunosuppression: implications for the prevention and prediction of post-stroke infections

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Miro Mur, Francesc
  • Montaner Villalonga, Joan
Immunosupressió; Infecció; Ictus, Inmunosupresión; Infección; Ictus, Immunosuppression; Infection; Stroke, Stroke produces a powerful inflammatory cascade in the brain, but also a suppression of the peripheral immune system, which is also called stroke-induced immunosuppression (SIIS). The main processes that lead to SIIS are a shift from a lymphocyte phenotype T-helper (Th) 1 to a Th2 phenotype, a decrease of the lymphocyte counts and NK cells in the blood and spleen, and an impairment of the defense mechanisms of neutrophils and monocytes. The direct clinical consequence of SIIS in stroke patients is an increased susceptibility to stroke-associated infections, which is enhanced by clinical factors like dysphagia. Among these infections, stroke-associated pneumonia (SAP) is the one that accounts for the highest impact on stroke outcome, so research is focused on its early diagnosis and prevention. Biomarkers indicating modifications in SIIS pathways could have an important role in the early prediction of SAP, but currently, there are no individual biomarkers or panels of biomarkers that are accurate enough to be translated to clinical practice. Similarly, there is still no efficient therapy to prevent the onset of SAP, and clinical trials testing prophylactic antibiotic treatment and β-blockers have failed. However, local immunomodulation could open up a new research opportunity to find a preventive therapy for SAP. Recent studies have focused on the pulmonary immune changes that could be caused by stroke similarly to other acquired brain injuries. Some of the traits observed in animal models of stroke include lung edema and inflammation, as well as inflammation of the bronchoalveolar lavage fluid., This project received funding from Instituto de Salud Carlos III (ISCIII) [PI17/02130], co-financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ [RD16/0019/0021].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Identifying new blood biomarkers of neuroplasticity associated with rehabilitation outcomes after stroke

  • García Rodríguez, Nicolás
  • García-Gabilondo, Miguel
  • Rodriguez, Susana
  • Tejada Ezquerro, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez-Mesquida, Maria Engracia
  • Valor-Blanquer, Júlia
  • Penalba Morenilla, Anna
  • Pérez, Laura Mónica
  • Inzitari, Marco
  • Lamana Vallverdú, Marcel
  • Delgado Martínez, María Pilar
  • Rosell Novel, Anna
Biomarker; Neuroplasticity; Recovery, Biomarcador; Neuroplasticitat; Recuperació, Biomarcador; Neuroplasticidad; Recuperación, Blood biomarkers in stroke patients seek to guide decision-making in clinical practice, but research on those that respond to brain recovery and their relationship with rehabilitation is still limited. Our aim was to explore the value of known neuroplasticity-related molecules, such as endostatin, growth and differentiation factor-10 (GDF-10), urokinase-type plasminogen activator (uPA) and the uPA receptor (uPAR), as blood biomarkers of recovery during poststroke rehabilitation. In an observational, prospective and multicenter study, biomarker levels were assessed after stroke in a cohort of 62 stroke patients with outcome evaluations and blood sampling before starting rehabilitation and during therapy at 1, 3 and 6 months of first visit, and in 43 control subjects. Serum levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) together with a complete battery of sensorimotor and functional tests/scales: modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA) for the upper extremity, Functional Ambulation Categories (FAC), Chedoke Arm and Hand Activity Inventory (CAHAI), 10-m walk test and the Medical Research Council (MRC). Statistical mixed linear models were built to investigate its prognostic value. The results revealed that, compared to controls, only endostatin was significantly increased at baseline after stroke (p < 0.01). Interestingly, the highest baseline GDF-10 or uPAR values were related to unfavorable scores during the complete follow-up (p < 0.05 for walking speed or MRC with GDF-10, and for FMA or MRC with uPAR), whereas decreased endostatin or increased GDF-10 biomarker changes at first month of rehabilitation were related to greater sensorimotor and functional improvements during follow-up (p < 0.05 for FMA or MRC with endostatin, and CAHAI or BI with GDF-10). Our results position endostatin, GDF-10 and uPAR as potential blood biomarkers to monitor recovery during rehabilitation after stroke., N.G-R. is doing a doctorate at the Departament de Medicina de la Universitat Autònoma de Barcelona. Research grants from the Instituto de Salud Carlos III with European Regional Development or Next Generation Founds to A.R. or J.B.S. supported this study (PI16/00981, PI19/00186, RD16/0019/0021, RD16/0019/0008, RD21/0006/0007, and RD21/0006/0014), as well as the 2021-SGR-0656 programme from the Generalitat de Catalunya-AGAUR. N.G-R. received a predoctoral fellowship from VHIR, and MG-G. received a research support grant (PERIS, SLT017/20/000197).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Faura Llorens, Julia
  • Penalba Morenilla, Anna
  • Pizarro Gonzálvez, Jesús
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Vert Soler, Carla
  • Rovira Cañellas, Alex
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Aquaporina 4; Angiopatia amiloide cerebral; Marcadors d'imatge per ressonància magnètica, Acuaporina 4; Angiopatía amiloide cerebral; Marcadores de imágenes por resonancia magnética, Aquaporin 4; Cerebral amyloid angiopathy; Magnetic resonance imaging markers, Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH., This research was funded by the Instituto de Salud Carlos III (ISCIII), (PI17/00275 and PI20/00465), co-financed by the European Regional Development Fund FEDER. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. was supported by the Miguel Servet programme, ISCIII, Spain (CPII17/00010). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Interaction of Sex and Diabetes on Outcome After Ischemic Stroke

  • Soriano-Reixach, Maria Montserrat
  • Vivanco-Hidalgo, Rosa Maria|||0000-0001-7547-0291
  • Ois, Angel|||0000-0002-1375-5950
  • Rodriguez Campello, Ana Maria|||0000-0001-8621-1420
  • Roquer González, Jaume|||0000-0001-5992-2606
The relationship between ischemic stroke (IS), diabetes mellitus (DM), and sex is intriguing. The aim of this study was to assess the effect modification of sex in the association between DM and short- and long-term disability and mortality in first-ever IS patients. In a retrospective, observational, hospital-based study of a prospective series including first-ever IS patients from January 2006 until July 2011, differences in 3-month and 5-year mortality, and disability between diabetic and non-diabetic patients [modified Rankin Scale (mRS) from 3 to 5] were analyzed by sex. In total, 933 patients (36.3% with DM, 50.5% women) were included. Overall 3-month and 5-year mortality were 150 (16.1%) and 407 (44.1%), respectively. Adjusted for age, previous mRS, and stroke severity, patients with DM had significantly higher 3-month disability [hazard ratio (HR): 1.49 (95% confidence interval (CI): 1.39-1.70), p < 0.0001], 5-year disability [HR: 1.41 (95% CI: 1.07-1.86), p = 0.015], and 5-year mortality [HR: 1.48 (95% CI: 1.20-1.81), p < 0.0001], compared with the non-DM group. Compared with non-DM women, women with diabetes had worse 3-month disability [HR: 1.81 (95% CI: 1.33-2.46), p < 0.0001] and 5-year mortality [HR: 1.72 (95% CI: 1.30-2.20), p < 0.0001], and a trend for 5-year disability [HR: 1.40 (95% CI: 0.99-2.09), p = 0.057]. In men, DM had an effect on 3-month disability [HR: 1.45 (95% CI: 1.07-1.96), p = 0.018], a trend for 5-year disability [HR: 1.43 (95% CI: 0.94-2.19), p = 0.096], but no clear effect on 5-year mortality [HR: 1.22 (95% CI: 0.91-1.65), p = 0.186]. Sex has a modifier effect on mortality in first-ever IS diabetic patients. Long-term mortality is increased in diabetic women compared with non-diabetic women, a difference not observed in men.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke

  • Puig, Josep|||0000-0003-2791-6599
  • Blasco, Gerard|||0000-0002-5302-0625
  • Daunis-i-Estadella, Pepus|||0000-0001-6134-9255
  • Eendendburg, Cecile van
  • Carrillo-García, María
  • Aboud, Carlos
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Serena, Joaquín|||0000-0002-4478-7744
  • Biarnés, Carles|||0000-0002-6604-2014
  • Nael, Kambiz
  • Liebeskind, David S.|||0000-0002-5109-8736
  • Thomalla, Götz
  • Menon, Bijoy K.
  • Demchuk, Andrew
  • Wintermark, Max
  • Pedraza, Salvador
  • Castellanos, María del Mar|||0000-0003-3116-1352
Objective. Blood-brain barrier (BBB) permeability has been proposed as a predictor of hemorrhagic transformation (HT) after tissue plasminogen activator (tPA) administration; however, the reliability of perfusion computed tomography (PCT) permeability imaging for predicting HT is uncertain. We aimed to determine the performance of high-permeability region size on PCT (HPrs- PCT) in predicting HT after intravenous tPA administration in patients with acute stroke. Methods. We performed a multimodal CT protocol (non-contrast CT, PCT, CT angiography) to prospectively study patients with middle cerebral artery occlusion treated with tPA within 4.5 hours of symptom onset. HT was graded at 24 hours using the European-Australasian Acute Stroke Study II criteria. ROC curves selected optimal volume threshold, and multivariate logistic regression analysis identified predictors of HT. Results. The study included 156 patients (50% male, median age 75.5 years). Thirty-seven (23,7%) developed HT [12 (7,7%), parenchymal hematoma type 2 (PH-2)]. At admission, patients with HT had lower platelet values, higher NIHSS scores, increased ischemic lesion volumes,larger HPrs-PCT, and poorer collateral status. The negative predictive value of HPrs-PCT at a threshold of 7mL/100g/min was 0.84 for HT and 0.93 for PH-2. The multiple regression analysis selected HPrs-PCT at 7mL/100g/min combined with platelets and baseline NIHSS score as the best model for predicting HT (AUC 0.77). HPrs-PCT at 7mL/100g/min was the only independent predictor of PH-2 (OR 1, AUC 0.68, p = 0.045). Conclusions. HPrs-PCT can help predict HT after tPA, and is particularly useful in identifying patients at low risk of developing HT.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis

  • Fernández-de-Retana, Sofía|||0000-0002-6350-8640
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Marazuela, Paula|||0000-0003-1038-5242
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Montañola, Alex
  • Montaner, Joan|||0000-0003-4845-2279
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Hernández Guillamón, Maria Mar
Cerebral β-amyloidosis is a major feature of Alzheimer's disease (AD), characterized by the accumulation of β-amyloid protein (Aβ) in the brain. Several studies have implicated lipid/lipoprotein metabolism in the regulation of β-amyloidosis. In this regard, HDL (High Density Lipoprotein)-based therapies could ameliorate pathological features associated with AD. As apolipoprotein J (ApoJ) is a natural chaperone that interacts with Aβ, avoiding its aggregation and toxicity, in this study we propose to prepare reconstituted rHDL-rApoJ nanoparticles by assembling phospholipids with recombinant human ApoJ (rApoJ). Hence, rHDL particles were prepared using the cholate dialysis method and characterized by N-PAGE, dynamic light scattering, circular dichroism and electron transmission microscopy. The preparation of rHDL particles showed two-sized populations with discoidal shape. Functionally, rHDL-rApoJ maintained the ability to prevent the Aβ fibrillization and mediated a higher cholesterol efflux from cultured macrophages. Fluorescently-labelled rHDL-rApoJ nanoparticles were intravenously administrated in mice and their distribution over time was determined using an IVIS Xenogen® imager. It was confirmed that rHDL-rApoJ accumulated in the cranial region, especially in old transgenic mice presenting a high cerebral Aβ load. In conclusion, we have standardized a reproducible protocol to produce rHDL-rApoJ nanoparticles, which may be potentially considered as a therapeutic option for β-amyloid-related pathologies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice

  • Fernández-de-Retana, Sofía|||0000-0002-6350-8640
  • Marazuela, Paula|||0000-0003-1038-5242
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
  • Colell, Guillem
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Montaner, Joan|||0000-0003-4845-2279
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Hernández Guillamón, Maria Mar
Background: ApoJ/clusterin is a multifunctional protein highly expressed in the brain. The implication of ApoJ in β-amyloid (Aβ) fibrillization and clearance in the context of Alzheimer's disease has been widely studied, although the source and concentration of ApoJ that promotes or inhibits Aβ cerebral accumulation is not clear yet. ApoJ is abundant in plasma and approximately 20% can appear bound to HDL-particles. In this regard, the impact of plasmatic ApoJ and its lipidation status on cerebral β-amyloidosis is still not known. Hence, our main objective was to study the effect of a peripheral increase of free ApoJ or reconstituted HDL particles containing ApoJ in an experimental model of cerebral β-amyloidosis. Methods: Fourteen-month-old APP23 transgenic mice were subjected to subchronic intravenous treatment with rHDL-rApoJ nanodiscs or free rApoJ for 1 month. Aβ concentration and distribution in the brain, as well as Aβ levels in plasma and CSF, were determined after treatments. Other features associated to AD pathology, such as neuronal loss and neuroinflammation, were also evaluated. Results: Both ApoJ-based treatments prevented the Aβ accumulation in cerebral arteries and induced a decrease in total brain insoluble Aβ levels. The peripheral treatment with rApoJ also induced an increase in the Aβ levels in CSF, whereas the concentration remained unaltered in plasma. At all the endpoints studied, the lipidation of rApoJ did not enhance the protective properties of free rApoJ. The effects obtained after subchronic treatment with free rApoJ were accompanied by a reduction in hippocampal neuronal loss and an enhancement of the expression of a phagocytic marker in microglial cells surrounding Aβ deposits. Finally, despite the activation of this phagocytic phenotype, treatments did not induce a global neuroinflammatory status. In fact, free rApoJ treatment was able to reduce the levels of interleukin-17 (IL17) and keratinocyte chemoattractant (KC) chemokine in the brain. Conclusions: Our results demonstrate that an increase in circulating human rApoJ induces a reduction of insoluble Aβ and CAA load in the brain of APP23 mice. Thus, our study suggests that peripheral interventions, based on treatments with multifunctional physiological chaperones, offer therapeutic opportunities to regulate the cerebral Aβ load.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease, Baseline results of the PRECISED study

  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Bañeras, Jordi|||0000-0002-7395-0862
  • Hernández, Cristina|||0000-0002-3109-1721
  • Rodríguez Palomares, José Fernando|||0000-0002-8822-5532
  • Valente, Filipa|||0000-0002-5569-3292
  • Gutiérrez García-Moreno, Laura
  • González-Alujas, Teresa
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
  • Aguadé-Bruix, Santiago|||0000-0001-8617-6274
  • Montaner, Joan|||0000-0003-4845-2279
  • Seron, Daniel|||0000-0003-2054-653X
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Boixadera Espax, Anna
  • García Arumí, José|||0000-0001-8827-1160
  • Planas, Alejandra
  • Simó-Servat, Olga|||0000-0003-3483-652X
  • García-Dorado, David|||0000-0002-1126-1279
Objective Detection of subclinical cardiovascular disease (CVD) has significant impact on the management of type 2 diabetes. We examined whether the assessment of diabetic retinopathy (DR) is useful for identifying patients at a higher risk of having silent CVD. Research design and methods Prospective case-control study comprising 200 type 2 diabetic subjects without history of clinical CVD and 60 age-matched non-diabetic subjects. The presence of subclinical CVD was examined using two parameters: (1) calcium coronary score (CACs); (2) composite of CACs.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Deciphering the iron side of stroke, Neurodegeneration at the crossroads between iron dyshomeostasis, excitotoxicity, and ferroptosis

  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • Martí-Sistac, O.
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
In general, iron represents a double-edged sword in metabolism in most tissues, especially in the brain. Although the high metabolic demands of brain cells require iron as a redox-active metal for ATP-producing enzymes, the brain is highly vulnerable to the devastating consequences of excessive iron-induced oxidative stress and, as recently found, to ferroptosis as well. The blood-brain barrier (BBB) protects the brain from fluctuations in systemic iron. Under pathological conditions, especially in acute brain pathologies such as stroke, the BBB is disrupted, and iron pools from the blood gain sudden access to the brain parenchyma, which is crucial in mediating stroke-induced neurodegeneration. Each brain cell type reacts with changes in their expression of proteins involved in iron uptake, efflux, storage, and mobilization to preserve its internal iron homeostasis, with specific organelles such as mitochondria showing specialized responses. However, during ischemia, neurons are challenged with excess extracellular glutamate in the presence of high levels of extracellular iron; this causes glutamate receptor overactivation that boosts neuronal iron uptake and a subsequent overproduction of membrane peroxides. This glutamate-driven neuronal death can be attenuated by iron-chelating compounds or free radical scavenger molecules. Moreover, vascular wall rupture in hemorrhagic stroke results in the accumulation and lysis of iron-rich red blood cells at the brain parenchyma and the subsequent presence of hemoglobin and heme iron at the extracellular milieu, thereby contributing to iron-induced lipid peroxidation and cell death. This review summarizes recent progresses made in understanding the ferroptosis component underlying both ischemic and hemorrhagic stroke subtypes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Usefulness of TNFR1 as biomarker of intracranial aneurysm in patients with spontaneous subarachnoid hemorrhage

  • de Torres-Chacón, Reyes
  • Mancha, Fernando|||0000-0003-0310-0894
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Canhao, Patricia
  • Fragata, Isabel
  • Montaner, Joan|||0000-0003-4845-2279
To determine the utility of TNF-α receptor (TNFR1) as a biomarker for the presence of aneurysms in patients with acute subarachnoid hemorrhage (SAH). This is a prospective study in patients with acute spontaneous SAH. Arterial blood from catheter near aneurysm and peripheral venous blood samples are collected. TNFR1 levels were analyzed in patients with and without aneurysm. 80 patients were included, 58 were analyzed. 41 patients (70.7%) had an aneurysm. Venous TNFR1 levels >1658 pg/ml had 46.3% sensitivity and 94.1% specificity for aneurysms presence. TNFR1 >1658 pg/ml was also an independent predictor for its presence (odds ratio = 12.03 [1.13–128.16]; p = 0.039). High levels of TNFR1 in peripheral venous blood are associated with the presence of aneurysm in patients with acute SAH. Subarachnoid hemorrhage (SAH) is a neurological emergency, in many cases caused by the rupture of a cerebral aneurysm. Usually aneurysms are detected in imaging tests, but sometimes they can be very small and go unnoticed. TNF-α is an inflammatory biomarker related to the presence and rupture of intracranial aneurysms and its receptor, TNFR1, could be detected in peripheral blood. This study demonstrates that elevated peripheral blood TNFR1 values are related to the presence of intracranial aneurysms in patients with acute subarachnoid hemorrhage. Following further research, it could become a useful tool for detecting small aneurysms in addition to conventional imaging tests.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Relevance of Porcine Stroke Models to Bridge the Gap from Pre-Clinical Findings to Clinical Implementation

  • Melià Sorolla, Marc|||0000-0002-4425-1077
  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • Rodríguez-Esparragoza, Luis
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Martí-Sistac, Octavi
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
  • Castaño Duque, Carlos|||0000-0001-9165-340X
In the search of animal stroke models providing translational advantages for biomedical research, pigs are large mammals with interesting brain characteristics and wide social acceptance. Compared to rodents, pigs have human-like highly gyrencephalic brains. In addition, increasingly through phylogeny, animals have more sophisticated white matter connectivity; thus, ratios of white-to-gray matter in humans and pigs are higher than in rodents. Swine models provide the opportunity to study the effect of stroke with emphasis on white matter damage and neuroanatomical changes in connectivity, and their pathophysiological correlate. In addition, the subarachnoid space surrounding the swine brain resembles that of humans. This allows the accumulation of blood and clots in subarachnoid hemorrhage models mimicking the clinical condition. The clot accumulation has been reported to mediate pathological mechanisms known to contribute to infarct progression and final damage in stroke patients. Importantly, swine allows trustworthy tracking of brain damage evolution using the same non-invasive multimodal imaging sequences used in the clinical practice. Moreover, several models of comorbidities and pathologies usually found in stroke patients have recently been established in swine. We review here ischemic and hemorrhagic stroke models reported so far in pigs. The advantages and limitations of each model are also discussed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Search for Reliable Circulating Biomarkers to Predict Carotid Plaque Vulnerability

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Jiménez Xarrié, Elena|||0000-0003-3567-0672
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Benitez, Sonia|||0000-0003-3565-0743
Atherosclerosis is responsible for 20% of ischemic strokes, and the plaques from the internal carotid artery the most frequently involved. Lipoproteins play a key role in carotid atherosclerosis since lipid accumulation contributes to plaque progression and chronic inflammation, both factors leading to plaque vulnerability. Carotid revascularization to prevent future vascular events is reasonable in some patients with high-grade carotid stenosis. However, the degree of stenosis alone is not sufficient to decide upon the best clinical management in some situations. In this context, it is essential to further characterize plaque vulnerability, according to specific characteristics (lipid-rich core, fibrous cap thinning, intraplaque hemorrhage). Although these features can be partly detected by imaging techniques, identifying carotid plaque vulnerability is still challenging. Therefore, the study of circulating biomarkers could provide adjunctive criteria to predict the risk of atherothrombotic stroke. In this regard, several molecules have been found altered, but reliable biomarkers have not been clearly established yet. The current review discusses the concept of vulnerable carotid plaque, and collects existing information about putative circulating biomarkers, being particularly focused on lipid-related and inflammatory molecules.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparative Proteomics Unveils LRRFIP1 as a New Player in the DAPK1 Interactome of Neurons Exposed to Oxygen and Glucose Deprivation

  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • Guirao, Verónica
  • Ponce, Jovita
  • Melià Sorolla, Marc|||0000-0002-4425-1077
  • Aliena-Valero, Alicia
  • García Serran, Alexia|||0000-0003-1630-1302
  • Salom, Juan B.|||0000-0002-4162-6101
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Martí-Sistac, Octavi
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
Death-associated protein kinase 1 (DAPK1) is a pleiotropic hub of a number of networked distributed intracellular processes. Among them, DAPK1 is known to interact with the excitotoxicity driver NMDA receptor (NMDAR), and in sudden pathophysiological conditions of the brain, e.g., stroke, several lines of evidence link DAPK1 with the transduction of glutamate-induced events that determine neuronal fate. In turn, DAPK1 expression and activity are known to be affected by the redox status of the cell. To delineate specific and differential neuronal DAPK1 interactors in stroke-like conditions in vitro, we exposed primary cultures of rat cortical neurons to oxygen/glucose deprivation (OGD), a condition that increases reactive oxygen species (ROS) and lipid peroxides. OGD or control samples were co-immunoprecipitated separately, trypsin-digested, and proteins in the interactome identified by high-resolution LC-MS/MS. Data were processed and curated using bioinformatics tools. OGD increased total DAPK1 protein levels, cleavage into shorter isoforms, and dephosphorylation to render the active DAPK1 form. The DAPK1 interactome comprises some 600 proteins, mostly involving binding, catalytic and structural molecular functions. OGD up-regulated 190 and down-regulated 192 candidate DAPK1-interacting proteins. Some differentially up-regulated interactors related to NMDAR were validated by WB. In addition, a novel differential DAPK1 partner, LRRFIP1, was further confirmed by reverse Co-IP. Furthermore, LRRFIP1 levels were increased by pro-oxidant conditions such as ODG or the ferroptosis inducer erastin. The present study identifies novel partners of DAPK1, such as LRRFIP1, which are suitable as targets for neuroprotection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of plasma lipoprotein composition and function in cerebral amyloid angiopathy and Alzheimer's disease

  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Fernández-de-Retana, Sofía|||0000-0002-6350-8640
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Pujadas, Francesc|||0000-0003-3569-2601
  • Freijo, Maria del Mar
  • Tur, Silvia
  • Martinez Zabaleta, Maite
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vera, Rocío
  • Lebrato-Hernández, Lucia|||0000-0002-3541-0697
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Pérez-Sánchez, Soledad|||0000-0002-8940-9763
  • Montaner, Joan|||0000-0003-4845-2279
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer's disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke

  • Ramiro, Laura|||0000-0002-4121-4609
  • Abraira del Fresno, Laura|||0000-0002-5119-7929
  • Quintana, Manuel|||0000-0003-0288-9088
  • García-Rodríguez, Paula|||0000-0001-6596-8002
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Zaragoza, Josep
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Ustrell, Xavier
  • Lara-Rodríguez, Blanca|||0009-0003-4534-9687
  • Terceño, Mikel|||0000-0001-5532-5329
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Montaner, Joan|||0000-0003-4845-2279
Stroke is a major cause of disability and death globally, and prediction of mortality represents a crucial challenge. We aimed to identify blood biomarkers measured during acute ischemic stroke that could predict long-term mortality. Nine hundred and forty-one ischemic stroke patients were prospectively recruited in the Stroke-Chip study. Post-stroke mortality was evaluated during a median 4.8-year follow-up. A 14-biomarker panel was analyzed by immunoassays in blood samples obtained at hospital admission. Biomarkers were normalized and standardized using Z -scores. Multiple Cox regression models were used to identify clinical variables and biomarkers independently associated with long-term mortality and mortality due to stroke. In the multivariate analysis, the independent predictors of long-term mortality were age, female sex, hypertension, glycemia, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Independent blood biomarkers predictive of long-term mortality were endostatin.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Electronegative LDL Promotes Inflammation and Triglyceride Accumulation in Macrophages

  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Montolio, Lara
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Navarra, Laia
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • Jiménez Xarrié, Elena|||0000-0003-3567-0672
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Electronegative low-density lipoprotein (LDL) (LDL(-)), a modified LDL that is present in blood and exerts atherogenic effects on endothelial cells and monocytes. This study aimed to determine the action of LDL(-) on monocytes differentiated into macrophages. LDL(-) and in vitro-modified LDLs (oxidized, aggregated, and acetylated) were added to macrophages derived from THP1 monocytes over-expressing CD14 (THP1-CD14). Then, cytokine release, cell differentiation, lipid accumulation, and gene expression were measured by ELISA, flow cytometry, thin-layer chromatography, and real-time PCR, respectively. LDL(-) induced more cytokine release in THP1-CD14 macrophages than other modified LDLs. LDL(-) also promoted morphological changes ascribed to differentiated macrophages. The addition of high-density lipoprotein (HDL) and anti-TLR4 counteracted these effects. LDL(-) was highly internalized by macrophages, and it was the major inductor of intracellular lipid accumulation in triglyceride-enriched lipid droplets. In contrast to inflammation, the addition of anti-TLR4 had no effect on lipid accumulation, thus suggesting an uptake pathway alternative to TLR4. In this regard, LDL(-) upregulated the expression of the scavenger receptors CD36 and LOX-1, as well as several genes involved in triglyceride (TG) accumulation. The importance and novelty of the current study is that LDL(-), a physiologically modified LDL, exerted atherogenic effects in macrophages by promoting differentiation, inflammation, and triglyceride-enriched lipid droplets formation in THP1-CD14 macrophages, probably through different receptors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke-Associated Complications

  • Faura, Júlia|||0000-0002-8436-1377
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Reverté, Silvia|||0000-0002-2052-9978
  • García-Berrocoso, Teresa|||0000-0001-7387-7389
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Castellanos, María del Mar|||0000-0003-3116-1352
  • Lara-Rodríguez, Blanca|||0009-0003-4534-9687
  • Zaragoza, Josep
  • Ventura, Oriol
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • van Eendenburg, Cecile
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Cánovas Verge, David|||0000-0002-3483-8106
  • Serena, Joaquín|||0000-0002-4478-7744
  • Rubiera Del Fueyo, Marta A.|||0000-0001-8100-9477
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Montaner, Joan|||0000-0003-4845-2279
Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life-threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Nine hundred thirty-eight patients experiencing ischemic stroke were prospectively recruited in the Stroke-Chip study. Post-stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log-transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10-fold cross-validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three-biomarker panels were developed as predictors: vascular adhesion protein-1.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Article targeting pro-oxidant iron with deferoxamine as a treatment for ischemic stroke, safety and optimal dose selection in a randomized clinical trial

  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • Pérez de la Ossa, Natalia|||0000-0002-6063-211X
  • Reverté, Silvia|||0000-0002-2052-9978
  • Costa Pages, Joan
  • Giner, Pilar
  • Silva, Yolanda
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Rodríguez-Yáñez, Manuel
  • Nombela, Florentino
  • Campos, Francisco|||0000-0001-8665-1039
  • Serena, Joaquín|||0000-0002-4478-7744
  • Vivancos, José
  • Martí-Sistac, Octavi
  • Cortés, Jordi|||0000-0002-3764-0795
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
A role of iron as a target to prevent stroke-induced neurodegeneration has been recently revisited due to new evidence showing that ferroptosis inhibitors are protective in experimental ischemic stroke and might be therapeutic in other neurodegenerative brain pathologies. Ferroptosis is a new form of programmed cell death attributed to an overwhelming lipidic peroxidation due to excessive free iron and reactive oxygen species (ROS). This study aims to evaluate the safety and tolerability and to explore the therapeutic efficacy of the iron chelator and antioxidant deferoxamine mesylate (DFO) in ischemic stroke patients. Administration of placebo or a single DFO bolus followed by a 72 h continuous infusion of three escalating doses was initiated during the tPA infusion, and the impact on blood transferrin iron was determined. Primary endpoint was safety and tolerability, and secondary endpoint was good clinical outcome (clinicalTrials.gov NCT00777140). DFO was found safe as adverse effects were not different between placebo and DFO arms. DFO (40-60 mg/Kg/day) reduced the iron saturation of blood transferrin. A trend to efficacy was observed in patients with moderate-severe ischemic stroke (NIHSS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cold stress protein RBM3 responds to hypothermia and is associated with good stroke outcome

  • Ávila-Gómez, Paulo
  • Vieites-Prado, Alba
  • Dopico-López, Antonio
  • Bashir, Saima
  • Fernández-Susavila, Héctor
  • Gubern, Carme|||0000-0001-8378-4477
  • Pérez-Mato, María
  • Correa-Paz, Clara
  • Iglesias-Rey, Ramón|||0000-0002-9985-9135
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Wellmann, Sven
  • Montaner, Joan|||0000-0003-4845-2279
  • Serena, Joaquín|||0000-0002-4478-7744
  • Castillo, José
  • Hervella, Pablo|||0000-0003-1249-6333
  • Campos, Francisco|||0000-0001-8665-1039
RNA-binding motif protein 3 is a molecular marker of hypothermia that has proved neuroprotective in neurodegenerative disease models. However, its relationship to the well-recognized therapeutic effect of hypothermia in ischaemic stroke had not been studied. In this work, the expression of RNA-binding motif protein 3 was investigated in ischaemic animal models subjected to systemic and focal brain hypothermia, specifically the effects of RNA-binding motif protein 3 silencing and overexpression on ischaemic lesions. Moreover, the association of RNA-binding motif protein 3 levels with body temperature and clinical outcome was evaluated in two independent cohorts of acute ischaemic stroke patients (n = 215); these levels were also determined in a third cohort of 31 patients derived from the phase III EuroHYP-1 trial of therapeutic cooling in ischaemic stroke. The preclinical data confirmed the increase of brain RNA-binding motif protein 3 levels in ischaemic animals subjected to systemic and focal hypothermia; this increase was selectively higher in the cooled hemisphere of animals undergoing focal brain hypothermia, thus confirming the direct effect of hypothermia on RNA-binding motif protein 3 expression, while RNA-binding motif protein 3 up-regulation in ischaemic brain regions led to functional recovery. Clinically, patients with body temperature <37.5°C in the first two cohorts had higher RNA-binding motif protein 3 values at 24 h and good outcome at 3 months post-ischaemic stroke, while RNA-binding motif protein 3 levels in the cooled third cohort tended to exceed those in placebo-treated patients. These results make RNA-binding motif protein 3 a molecular marker associated with the effect of hypothermia in ischaemic stroke and suggest its potential application as a promising protective target. Hypothermia is an effective neuroprotective treatment in stroke. We have demonstrated that the expression of RBM3 is increased under hypothermia treatment in animal models of ischaemia and stroke patients. These results evidence the potential application of RBM3 as a promising protective target against ischaemia
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Glycemic variability, prognostic impact on acute ischemic stroke and the impact of corrective treatment for hyperglycemia. The GLIAS-III translational study

  • Fuentes, Blanca|||0000-0002-0363-862X
  • Pastor-Yborra, Silvia
  • Gutiérrez-Zúñiga, Raquel
  • González-Pérez de Villar, Noemí
  • Celis Ruiz, Elena de|||0000-0002-9224-9422
  • Rodríguez-Pardo, Jorge
  • Gómez-de Frutos, Mari Carmen
  • Laso-García, Fernando
  • Gutiérrez-Fernández, María
  • Ortega-Casarrubios, MÁngeles
  • Soto González, Alfonso
  • López-Fernández, María
  • Santamaría, María
  • Díez-González, Noemí
  • Freijo, Mar M.
  • Zandio, Beatriz
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Calleja, Ana
  • Portilla-Cuenca, Juan Carlos
  • Lisbona, Arturo
  • Otero-Ortega, Laura
  • Díez-Tejedor, Exuperio
Glycemic variability (GV) represents the amplitude of oscillations in glucose levels over time and is associated with higher mortality in critically ill patients. Our aim is to evaluate the impact of GV on acute ischemic stroke (IS) outcomes in humans and explore the impact of two different insulin administration routes on GV in an animal model. This translational study consists of two studies conducted in parallel: The first study is an observational, multicenter, prospective clinical study in which 340 patients with acute IS will be subcutaneously implanted a sensor to continuously monitor blood glucose levels for 96 h. The second study is a basic experimental study using an animal model (rats) with permanent occlusion of the middle cerebral artery and induced hyperglycemia (through an intraperitoneal injection of nicotinamide and streptozotocin). The animal study will include the following 6 groups (10 animals per group): sham; hyperglycemia without IS; IS without hyperglycemia; IS and hyperglycemia without treatment; IS and hyperglycemia and intravenous insulin; and IS and hyperglycemia and subcutaneous insulin. The endpoint for the first study is mortality at 3 months, while the endpoints for the animal model study are GV, functional recovery and biomarkers. The GLIAS-III study will be the first translational approach analyzing the prognostic influence of GV, evaluated by the use of subcutaneous glucose monitors, in acute stroke. Trial registration (NCT04001049).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MRI/Photoluminescence Dual-Modal Imaging Magnetic PLGA Nanocapsules for Theranostics

  • Zhang, Yajie|||0000-0003-1566-1007
  • García-Gabilondo, Miguel|||0000-0002-2015-2621
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Roig i Serra, Anna|||0000-0001-6464-7573
Developing multifunctional and biocompatible drug delivery nanoplatforms that integrate high drug loads and multiple imaging modalities avoiding cross-interferences is extremely challenging. Here we report on the successful chemical reaction of the high quantum yield biodegradable and photoluminescent polyester (BPLP) with the poly(lactic-co-glycolic acid) (PLGA) polymer to fabricate biocompatible photoluminescent nanocapsules (NCs). Furthermore, we transform the PLGA-BPLP NCs into a magnetic resonance (MR)/photoluminescence dual-modal imaging theranostic platform by incorporating superparamagnetic iron oxide nanoparticles (SPIONs) into the polymeric shell. In vitro phantoms confirmed the excellent MRI-r relaxivity values of the NCs whilst the cellular uptake of these NCs was clearly observed by fluorescence optical imaging. Besides, the NCs (mean size ~270 nm) were loaded with ~1 wt% of a model protein (BSA) and their PEGylation provided a more hydrophilic surface. The NCs show biocompatibility in vitro, as hCMEC/D3 endothelial cells viability was not affected for particle concentration up to 500 μg/mL. Interestingly, NCs decorated with SPIONs can be exploited for magnetic guiding and retention.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of the rat cerebrospinal fluid proteome following acute cerebral ischemia using an aptamer-based proteomic technology

  • Simats Oriol, Alba|||0000-0002-0415-1135
  • García-Berrocoso, Teresa|||0000-0001-7387-7389
  • Ramiro, Laura|||0000-0002-4121-4609
  • Giralt, Dolors
  • Gill, Natalia
  • Penalba, Anna
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Montaner, Joan|||0000-0003-4845-2279
The limited accessibility to the brain has turned the cerebrospinal fluid (CSF) into a valuable source that may contribute to the complete understanding of the stroke pathophysiology. Here we have described the CSF proteome in the hyper-acute phase of cerebral ischemia by performing an aptamer-based proteomic assay (SOMAscan) in CSF samples collected before and 30 min after male Wistar rats had undergone a 90 min Middle Cerebral Artery Occlusion (MCAO) or sham-surgery. Proteomic results indicated that cerebral ischemia acutely increased the CSF levels of 716 proteins, mostly overrepresented in leukocyte chemotaxis and neuronal death processes. Seven promising candidates were further evaluated in rat plasma and brain (CKB, CaMK2A, CaMK2B, CaMK2D, PDXP, AREG, CMPK). The 3 CaMK2 family-members and CMPK early decreased in the infarcted brain area and, together with AREG, co-localized with neurons. Conversely, CKB levels remained consistent after the insult and specifically matched with astrocytes. Further exploration of these candidates in human plasma revealed the potential of CKB and CMPK to diagnose stroke, while CaMK2B and CMPK resulted feasible biomarkers of functional stroke outcome. Our findings provided insights into the CSF proteome following cerebral ischemia and identified new outstanding proteins that might be further considered as potential biomarkers of stroke.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

  • Marazuela, Paula|||0000-0003-1038-5242
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Faura, Júlia|||0000-0002-8436-1377
  • Penalba, Anna
  • Pizarro Gonzálvez, Jesús|||0000-0002-5808-9293
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Vert, Carla
  • Rovira, Alex|||0000-0002-2132-6750
  • Pujadas, Francesc|||0000-0003-3569-2601
  • Freijo, M. Mar
  • Tur, Silvia
  • Martínez-Zabaleta, Maite
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vera, Rocío
  • Lebrato-Hernández, Lucia|||0000-0002-3541-0697
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Pérez-Sánchez, Soledad|||0000-0002-8940-9763
  • Montaner, Joan|||0000-0003-4845-2279
  • Delgado Martínez, María Pilar|||0000-0002-1628-4488
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA-ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SSAO/VAP-1 in Cerebrovascular Disorders, A Potential Therapeutic Target for Stroke and Alzheimer's Disease

  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
  • Sun, Ping|||0000-0001-6307-3723
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
The semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1) or primary amine oxidase (PrAO), is a deaminating enzyme highly expressed in vessels that generates harmful products as a result of its enzymatic activity. As a multifunctional enzyme, it is also involved in inflammation through its ability to bind and promote the transmigration of circulating leukocytes into inflamed tissues. Inflammation is present in different systemic and cerebral diseases, including stroke and Alzheimer's disease (AD). These pathologies show important affectations on cerebral vessels, together with increased SSAO levels. This review summarizes the main roles of SSAO/VAP-1 in human physiology and pathophysiology and discusses the mechanisms by which it can affect the onset and progression of both stroke and AD. As there is an evident interrelationship between stroke and AD, basically through the vascular system dysfunction, the possibility that SSAO/VAP-1 could be involved in the transition between these two pathologies is suggested. Hence, its inhibition is proposed to be an interesting therapeutical approach to the brain damage induced in these both cerebral pathologies
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Stroke-induced immunosuppression, implications for the prevention and prediction of post-stroke infections

  • Faura, Júlia|||0000-0002-8436-1377
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Miró-Mur, Francesc|||0000-0003-3936-2693
  • Montaner, Joan|||0000-0003-4845-2279
Stroke produces a powerful inflammatory cascade in the brain, but also a suppression of the peripheral immune system, which is also called stroke-induced immunosuppression (SIIS). The main processes that lead to SIIS are a shift from a lymphocyte phenotype T-helper (Th) 1 to a Th2 phenotype, a decrease of the lymphocyte counts and NK cells in the blood and spleen, and an impairment of the defense mechanisms of neutrophils and monocytes. The direct clinical consequence of SIIS in stroke patients is an increased susceptibility to stroke-associated infections, which is enhanced by clinical factors like dysphagia. Among these infections, stroke-associated pneumonia (SAP) is the one that accounts for the highest impact on stroke outcome, so research is focused on its early diagnosis and prevention. Biomarkers indicating modifications in SIIS pathways could have an important role in the early prediction of SAP, but currently, there are no individual biomarkers or panels of biomarkers that are accurate enough to be translated to clinical practice. Similarly, there is still no efficient therapy to prevent the onset of SAP, and clinical trials testing prophylactic antibiotic treatment and β-blockers have failed. However, local immunomodulation could open up a new research opportunity to find a preventive therapy for SAP. Recent studies have focused on the pulmonary immune changes that could be caused by stroke similarly to other acquired brain injuries. Some of the traits observed in animal models of stroke include lung edema and inflammation, as well as inflammation of the bronchoalveolar lavage fluid.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Survival Bias and Crosstalk between Chronological and Behavioral Age, Age- and Genotype-Sensitivity Tests Define Behavioral Signatures in Middle-Aged, Old, and Long-Lived Mice with Normal and AD-Associated Aging

  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • Marín-Pardo, Daniela|||0000-0002-0202-0334
  • Marazuela, Paula|||0000-0003-1038-5242
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
New evidence refers to a high degree of heterogeneity in normal but also Alzheimer's disease (AD) clinical and temporal patterns, increased mortality, and the need to find specific end-of-life prognosticators. This heterogeneity is scarcely explored in very old male AD mice models due to their reduced survival. In the present work, using 915 (432 APP23 and 483 C57BL/6 littermates) mice, we confirmed the better survival curves in male than female APP23 mice and respective wildtypes, providing the chance to characterize behavioral signatures in middle-aged, old, and long-lived male animals. The sensitivity of a battery of seven paradigms for comprehensive screening of motor (activity and gait analysis), neuropsychiatric and cognitive symptoms was analyzed using a cohort of 56 animals, composed of 12-, 18- and 24-month-old male APP23 mice and wildtype littermates. Most variables analyzed detected age-related differences. However, variables related to coping with stress, thigmotaxis, frailty, gait, and poor cognition better discriminated the behavioral phenotype of male APP23 mice through the three old ages compared with controls. Most importantly, non-linear age- and genotype-dependent behavioral signatures were found in long-lived animals, suggesting crosstalk between chronological and biological/behavioral ages useful to study underlying mechanisms and distinct compensations through physiological and AD-associated aging.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Angiogenin in the Neurogenic Subventricular Zone After Stroke

  • Gabriel Salazar, Marina|||0000-0002-7521-1502
  • Lei, Ting|||0000-0002-2787-5208
  • Grayston, Alba|||0000-0002-1466-0099
  • Costa, Carme|||0000-0001-9577-3839
  • Medina-Gutiérrez, Esperanza
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Montaner, Joan|||0000-0003-4845-2279
  • Rosell Novel, Anna|||0000-0003-1082-3599
Ischemic stroke is a leading cause of death and disability worldwide with effective acute thrombolytic treatments. However, brain repair mechanisms related to spontaneous or rehabilitation-induced recovery are still under investigation, and little is known about the molecules involved. The present study examines the potential role of angiogenin (ANG), a known regulator of cell function and metabolism linked to neurological disorders, focusing in the neurogenic subventricular zone (SVZ). Angiogenin expression was examined in the mouse SVZ and in SVZ-derived neural stem cells (NSCs), which were exposed to exogenous ANG treatment during neurosphere formation as well as in other neuron-like cells (SH-SY5Y). Additionally, male C57Bl/6 mice underwent a distal permanent occlusion of the middle cerebral artery to study endogenous and exercise-induced expression of SVZ-ANG and neuroblast migration. Our results show that SVZ areas are rich in ANG, primarily expressed in DCX+ neuroblasts but not in nestin+NSCs. In vitro, treatment with ANG increased the number of SVZ-derived NSCs forming neurospheres but could not modify SH-SY5Y neurite differentiation. Finally, physical exercise rapidly increased the amount of endogenous ANG in the ipsilateral SVZ niche after ischemia, where DCX-migrating cells increased as part of the post-stroke neurogenesis process. Our findings position for the first time ANG in the SVZ during post-stroke recovery, which could be linked to neurogenesis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteins and pathways in atrial fibrillation and atrial cardiomyopathy underlying cryptogenic stroke

  • Palà, Elena|||0000-0002-1074-990X
  • Pagola, Jorge|||0000-0002-0725-1369
  • Juega, Jesus|||0000-0003-1309-0730
  • Francisco Pascual, Jaume|||0000-0002-8841-2581
  • Penalba, Anna
  • Rodriguez, Maite
  • De Lera Alfonso, Mercedes|||0000-0002-3954-9071
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Cabezas, Juan Antonio
  • Moniche, Francisco|||0000-0001-8613-2909
  • de Torres-Chacón, Reyes
  • Pérez-Sánchez, Soledad|||0000-0002-8940-9763
  • González-Alujas, Teresa
  • Molina, Carlos A.|||0000-0001-6058-6259
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Montaner, Joan|||0000-0003-4845-2279
Atrial fibrillation (AF) is one of the most prevalent causes of cryptogenic stroke. Also, apart from AF itself, structural and remodelling changes in the atria might be an underlying cause of cryptogenic stroke. We aimed to discover circulating proteins and reveal pathways altered in AF and atrial cardiomyopathy, measured by left atrial volume index (LAVI) and peak atrial longitudinal strain (PALS), in patients with cryptogenic stroke. An aptamer array (including 1310 proteins) was measured in the blood of 20 cryptogenic stroke patients monitored during 28 days with a Holter device as a case-control study of the Crypto-AF cohort. Protein levels were compared between patients with (n = 10) and without AF (n = 10) after stroke, and the best candidates were tested in 111 patients from the same cohort (44 patients with AF and 67 without AF). In addition, in the first 20 patients, proteins were explored according to PALS and LAVI values. Forty-six proteins were differentially expressed in AF cases. Of those, four proteins were tested in a larger sample size. Only DPP7, presenting lower levels in AF patients, was further validated. Fifty-seven proteins correlated with LAVI, and 270 correlated with PALS. NT-proBNP was common in all the discovery analyses performed. Interestingly, many proteins and pathways were altered in patients with low PALS. Multiple proteins and pathways related to AF and atrial cardiomyopathy have been revealed. The role of DPP7 as a biomarker for stroke aetiology should be further explored. Moreover, the present study may be considered hypothesis-generating.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sleep/wake cycle alterations as a cause of neurodegenerative diseases, A Mendelian randomization study

  • Cullell, Natalia|||0000-0001-5118-1014
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Amaut, K.E.U.
  • Krupinski, J.
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Sleep and/or wake cycle alterations are common in neurodegenerative diseases (ND). Our aim was to determine whether there is a causal relationship between sleep and/or wake cycle patterns and ND (Parkinson's disease (PD) age at onset (AAO), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS)) using two-sample Mendelian Randomization (MR). We selected 12 sleep traits with available Genome-Wide Association Study (GWAS) to evaluate their causal relationship with the ND risk through Inverse-Variance Weighted regression as main analysis. We used as outcome the latest ND GWAS with available summary-statistics: PD-AAO (N = 17,996), AD (N = 21,235) and ALS (N = 40,136). MR results pointed to a causal effect of subjective and objective-measured morning chronotype on later PD-AAO (95%CI:0.33-1.81, p = 8.47×10 and 95%CI:-7.28 to -4.44, p = 5.87×10, respectively). Sleep efficiency was causally associated with a decreased AD risk (95%CI:-20.408 to -0.66, p = 0.04) and daytime sleepiness with an increased ALS risk (95%CI:0.15 to 1.61, p = 0.01). Our study suggests that sleep and/or wake patterns have causal relationship with ND. Given that sleep and/or wake patterns are modifiable risk factors, sleep interventions should be investigated as a potential treatment in PD-AAO, AD and ALS.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Presence of Ceramidase Activity in Electronegative LDL

  • Puig Calvó, Núria|||0000-0001-8235-4934
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Estruch, Montserrat|||0000-0002-7162-4158
  • Aguilera-Simón, Ana|||0000-0003-1428-8212
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Camacho, Mercedes|||0000-0001-5970-3294
  • Colomé, Núria
  • Canals, Francesc|||0000-0002-0650-1135
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Benitez, Sonia|||0000-0003-3565-0743
Electronegative low-density lipoprotein (LDL(-)) is a minor modified fraction of human plasma LDL with several atherogenic properties. Among them is increased bioactive lipid mediator content, such as lysophosphatidylcholine (LPC), non-esterified fatty acids (NEFA), ceramide (Cer), and sphingosine (Sph), which are related to the presence of some phospholipolytic activities, including platelet-activating factor acetylhydrolase (PAF-AH), phospholipase C (PLC), and sphingomyelinase (SMase), in LDL(-). However, these enzymes' activities do not explain the increased Sph content, which typically derives from Cer degradation. In the present study, we analyzed the putative presence of ceramidase (CDase) activity, which could explain the increased Sph content. Thin layer chromatography (TLC) and lipidomic analysis showed that Cer, Sph, and NEFA spontaneously increased in LDL(-) incubated alone at 37 °C, in contrast with native LDL(+). An inhibitor of neutral CDase prevented the formation of Sph and, in turn, increased Cer content in LDL(-). In addition, LDL(-) efficiently degraded fluorescently labeled Cer (NBD-Cer) to form Sph and NEFA. These observations defend the existence of the CDase-like activity's association with LDL(-). However, neither the proteomic analysis nor the Western blot detected the presence of an enzyme with known CDase activity. Further studies are thus warranted to define the origin of the CDase-like activity detected in LDL(-).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Establishment of a reproducible and minimally invasive ischemic stroke model in swine

  • Castaño Duque, Carlos|||0000-0001-9165-340X
  • Melià Sorolla, Marc|||0000-0002-4425-1077
  • García Serran, Alexia|||0000-0003-1630-1302
  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • García-Sort, Maria Rosa|||0000-0001-6531-6258
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Valls Carbó, Adrián|||0000-0002-4831-1276
  • Pino, Osvaldo
  • Grífols, Jordi|||0000-0002-7804-9846
  • Iruela-Sánchez, Alba|||0000-0002-1879-5601
  • Palomar-García, Alicia
  • Puig, Josep|||0000-0003-2791-6599
  • Martí-Sistac, Octavi
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
The need for advances in the management/treatment options for ischemic stroke patients requires that upcoming preclinical research uses animals with more human-like brain characteristics. The porcine brain is considered appropriate, although the presence of the rete mirabile (RM) prevents direct catheterization of the intracranial arteries to produce focal cerebral ischemia. To develop a reproducible minimally invasive porcine stroke model, a guide catheter and guide wire were introduced through the femoral artery until reaching the left RM. Using the pressure cooker technique, Squid-12 embolization material was deposited to fill, overflow, and occlude the left RM, the left internal carotid artery, and left circle of Willis wing up to the origins of the middle cerebral arteries (MCAs), mimicking the occlusion produced in the filament model in rodents. Longitudinal multimodal cerebral MRI was conducted to assess the brain damage and cerebral blood supply. The technique we describe here occluded up to the origins of the MCAs in 7 of 8 swine, inducing early damage 90 minutes after occlusion that later evolved to a large cerebral infarction and producing no mortality during the intervention. This minimally invasive ischemic stroke model in swine produced reproducible infarcts and shows translational features common to human stroke.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Functional Recovery and Serum Angiogenin Changes According to Intensity of Rehabilitation Therapy After Stroke

  • García Rodríguez, Nicolás|||0000-0001-8839-0514
  • Rodriguez Gonzalez, Susana|||0000-0002-6170-5253
  • Tejada, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier|||0000-0001-6814-7373
  • Pérez-Mesquida, María Engracia|||0000-0001-7949-7678
  • Beseler, Maria Rosario
  • Salom, Juan B.|||0000-0002-4162-6101
  • Pérez, Laura Mónica|||0000-0003-3152-9882
  • Inzitari, Marco|||0000-0002-3796-0625
  • Otero-Villaverde, Sergio
  • Martin-Mourelle, Rosa
  • Molleda, Mercedes|||0000-0001-5393-9837
  • Quintana, Manuel|||0000-0003-0288-9088
  • Olivé-Gadea, Marta|||0000-0003-4637-1598
  • Penalba, Anna
  • Rosell Novel, Anna|||0000-0003-1082-3599
Rehabilitation is still the only treatment available to improve functional status after the acute phase of stroke. Most clinical guidelines highlight the need to design rehabilitation treatments considering starting time, intensity, and frequency, according to the tolerance of the patient. However, there are no homogeneous protocols and the biological effects are under investigation. To investigate the impact of rehabilitation intensity (hours) after stroke on functional improvement and serum angiogenin (ANG) in a 6-month follow-up study. A prospective, observational, longitudinal, and multicenter study with three cohorts: strokes in intensive rehabilitation therapy (IRT, minimum 15 h/week) vs. conventional therapy (NO-IRT, <15 h/week), and controls subjects (without known neurological, malignant, or inflammatory diseases). A total of seven centers participated, with functional evaluations and blood sampling during follow-up. The final cohort includes 62 strokes and 43 controls with demographic, clinical, blood samples, and exhaustive functional monitoring. The median (IQR) number of weekly hours of therapy was different: IRT 15 (15-16) vs. NO-IRT 7.5 (5-9), p < 0.01, with progressive and significant improvements in both groups. However, IRT patients showed earlier improvements (within 1 month) on several scales (CAHAI, FMA, and FAC; p < 0.001) and the earliest community ambulation achievements (0.89 m/s at 3 months). There was a significant difference in ANG temporal profile between the IRT and NO-IRT groups (p < 0.01). Additionally, ANG was elevated at 1 month only in the IRT group (p < 0.05) whereas it decreased in the NO-IRT group (p < 0.05). Our results suggest an association of rehabilitation intensity with early functional improvements, and connect the rehabilitation process with blood biomarkers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain

  • Cullell, Natalia|||0000-0001-5118-1014
  • Carrera, Caty|||0000-0002-0804-0969
  • Muiño, Elena|||0000-0001-5839-7328
  • Torres-Aguila, Nuria|||0000-0002-9502-9310
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • González-Sánchez, Jonathan
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Molina, Jessica
  • Besora, Sarah
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • Buongiorno, María-Teresa
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • de Torres-Chacón, Reyes
  • Montaner, Joan|||0000-0003-4845-2279
  • Mancha, Fernando|||0000-0003-0310-0894
  • Cabezas, Juan Antonio
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Purroy, Francisco|||0000-0002-1808-5968
  • Cambray, Serafi
  • Freijo, María del Mar
  • Vives-Bauzá, Cristòfol|||0000-0001-5735-8335
  • Tur, Silvia
  • Font, Maria-Àngels
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Obach, Víctor|||0000-0002-0518-1053
  • Calleja, Ana
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Rodríguez-Yáñez, Manuel
  • Castillo, José
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Krupinski, Jerzy|||0000-0002-5136-8898
Acenocoumarol is an oral anticoagulant with significant interindividual dose variations. Variants in CYP2C9 and VKORC1 have been associated with acenocoumarol maintenance dose. We analysed whether any of the 49 polymorphisms in CYP2C9 and VKORC1 previously associated with acenocoumarol maintenance dose in a Genome-Wide Association study (GWAs) in Dutch population are associated with stroke recurrence, intracranial haemorrhage (ICH) and acenocoumarol maintenance dose in a Spanish population. We performed a GWAs using Human Core Exome-chip (Illumina) in 78 patients stroke patients treated with acenocoumarol for secondary prevention enrolled as part of the prospective investigator-initiated study (IIS) SEDMAN Study. Patients were followed-up a median of 12.8 months. Three and eight patients had recurrent stroke and ICH events, respectively. We found 14 of the 49 published variants associated with acenocoumarol maintenance dose (p < 0.05). Six polymorphisms were associated with stroke recurrence and four variants with ICH (p < 0.05). In conclusion, variants in VKORC1 and CYP2C9 are associated with acenocoumarol maintenance dose, stroke recurrence and ICH in a Spanish cohort. These results highlight the relevance of studying pharmacogenetics associated with efficacy and safety of anticoagulant drugs and justify studies with larger sample size and different ethnic populations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Statins do not increase Markers of Cerebral Angiopathies in patients with Cardioembolic Stroke

  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Medrano-Martorell, Santiago|||0000-0002-6586-7284
  • Merino, Elisa
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Marín-Bueno, Rebeca|||0000-0002-0354-6602
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Gómez-Choco, Manuel|||0000-0002-4191-7574
  • Lara, Lidia
  • Casado Naranjo, Ignacio
  • Cánovas Verge, David|||0000-0002-3483-8106
  • Torres, Maria José
  • Freijo, Marimar
  • Calleja, Ana
  • Bravo, Yolanda
  • Cocho, Dolores
  • Rodriguez Campello, Ana Maria|||0000-0001-8621-1420
  • Zandio, Beatriz
  • Fuentes, Blanca|||0000-0002-0363-862X
  • De Felipe, Alicia
  • Llull, Laura
  • Maestre Moreno, José|||0000-0002-5708-8272
  • Hernández, María
  • Garces, Moises|||0000-0002-1756-5492
  • De Arce-Borda, Ana Maria
  • Palomeras, Ernest|||0000-0002-0724-8653
  • Rodríguez-Yáñez, Manuel
  • Diáz-Maroto, Inma
  • Serrano, Marta
  • Fernández-Domínguez, Jessica
  • Sanahuja, Jordi
  • Purroy, Francisco|||0000-0002-1808-5968
  • Zedde, Marialuisa
  • Delgado-Mengual, Jordi
  • Gich, Ignasi|||0000-0003-3975-6588
We investigated whether pre-treatment with statins is associated with surrogate markers of amyloid and hypertensive angiopathies in patients who need to start long-term oral anticoagulation therapy. A prospective multicenter study of patients naive for oral anticoagulants, who had an acute cardioembolic stroke. MRI was performed at admission to evaluate microbleeds, leukoaraiosis and superficial siderosis. We collected data on the specific statin compound, the dose and the statin intensity. We performed bivariate analyses and a logistic regression to investigate variables associated with microbleeds. We studied 470 patients (age 77.5 ± 6.4 years, 43.7% were men), and 193 (41.1%) of them received prior treatment with a statin. Microbleeds were detected in 140 (29.8%), leukoaraiosis in 388 (82.5%) and superficial siderosis in 20 (4.3%) patients. The presence of microbleeds, leukoaraiosis or superficial siderosis was not related to pre-treatment with statins. Microbleeds were more frequent in patients with prior intracerebral hemorrhage (OR 9.7, 95% CI 1.06-90.9) and in those pre-treated antiplatelets (OR 1.66, 95% CI 1.09-2.53). Prior treatment with statins was not associated with markers of bleeding-prone cerebral angiopathies in patients with cardioembolic stroke. Therefore, previous statin treatment should not influence the decision to initiate or withhold oral anticoagulation if these neuroimaging markers are detected.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease

  • Camacho, Jessica|||0000-0001-8018-8274
  • Rábano, Alberto|||0000-0001-9320-6566
  • Marazuela, Paula|||0000-0003-1038-5242
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Serna, Garazi|||0000-0003-2666-0982
  • Moliné, Teresa|||0000-0003-4912-5114
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Martinez-Saez, Elena|||0000-0001-6004-5364
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Genome-wide association studies have described several genes as genetic susceptibility loci for Alzheimer's disease (AD). Among them, CD2AP encodes CD2-associated protein, a scaffold protein implicated in dynamic actin remodeling and membrane trafficking during endocytosis and cytokinesis. Although a clear link between CD2AP defects and glomerular pathology has been described, little is known about the function of CD2AP in the brain. The aim of this study was to analyze the distribution of CD2AP in the AD brain and its potential associations with tau aggregation and β-amyloid (Aβ) deposition. First, we performed immunohistochemical analysis of CD2AP expression in brain tissue from AD patients and controls (N = 60). Our results showed granular CD2AP immunoreactivity in the human brain endothelium in all samples. In AD cases, no CD2AP was found to be associated with Aβ deposits in vessels or parenchymal plaques. CD2AP neuronal inclusions similar to neurofibrillary tangles (NFT) and neuropil thread-like deposits were found only in AD samples. Moreover, immunofluorescence analysis revealed that CD2AP colocalized with pTau. Regarding CD2AP neuronal distribution, a hierarchical progression from the entorhinal to the temporal and occipital cortex was detected. We found that CD2AP immunodetection in neurons was strongly and positively associated with Braak neurofibrillary stage, independent of age and other pathological hallmarks. To further investigate the association between pTau and CD2AP, we included samples from cases of primary tauopathies (corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], and Pick's disease [PiD]) in our study. Among these cases, CD2AP positivity was only found in PiD samples as neurofibrillary tangle-like and Pick body-like deposits, whereas no neuronal CD2AP deposits were detected in PSP or CBD samples, which suggested an association of CD2AP neuronal expression with 3R-Tau-diseases. In conclusion, our findings open a new road to investigate the complex cellular mechanism underlying the tangle conformation and tau pathology in the brain.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Insulin receptor activation by proinsulin preserves synapses and vision in retinitis pigmentosa

  • Sánchez-Cruz, Alonso
  • Hernández-Pinto, Alberto
  • Lillo, Concepción|||0000-0001-5814-9826
  • Isiegas, Carolina
  • Marchena, Miguel
  • Lizasoain, Ignacio
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • de la Villa, Pedro|||0000-0001-9856-6616
  • Hernández-Sánchez, Catalina|||0000-0002-0846-5019
  • de la Rosa, Enrique J.|||0000-0001-9984-9706
Synaptic loss, neuronal death, and circuit remodeling are common features of central nervous system neurodegenerative disorders. Retinitis pigmentosa (RP), the leading cause of inherited blindness, is a group of retinal dystrophies characterized by photoreceptor dysfunction and death. The insulin receptor, a key controller of metabolism, also regulates neuronal survival and synaptic formation, maintenance, and activity. Indeed, deficient insulin receptor signaling has been implicated in several brain neurodegenerative pathologies. We present evidence linking impaired insulin receptor signaling with RP. We describe a selective decrease in the levels of the insulin receptor and its downstream effector phospho-S6 in retinal horizontal cell terminals in the rd10 mouse model of RP, as well as aberrant synapses between rod photoreceptors and the postsynaptic terminals of horizontal and bipolar cells. A gene therapy strategy to induce sustained proinsulin, the insulin precursor, production restored retinal insulin receptor signaling, by increasing S6 phosphorylation, without peripheral metabolic consequences. Moreover, proinsulin preserved photoreceptor synaptic connectivity and prolonged visual function in electroretinogram and optomotor tests. These findings point to a disease-modifying role of insulin receptor and support the therapeutic potential of proinsulin in retinitis pigmentosa.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Stroke-induced immunosuppression: implications for the prevention and prediction of post-stroke infections

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Miro Mur, Francesc
  • Montaner Villalonga, Joan
Immunosupressió; Infecció; Ictus, Inmunosupresión; Infección; Ictus, Immunosuppression; Infection; Stroke, Stroke produces a powerful inflammatory cascade in the brain, but also a suppression of the peripheral immune system, which is also called stroke-induced immunosuppression (SIIS). The main processes that lead to SIIS are a shift from a lymphocyte phenotype T-helper (Th) 1 to a Th2 phenotype, a decrease of the lymphocyte counts and NK cells in the blood and spleen, and an impairment of the defense mechanisms of neutrophils and monocytes. The direct clinical consequence of SIIS in stroke patients is an increased susceptibility to stroke-associated infections, which is enhanced by clinical factors like dysphagia. Among these infections, stroke-associated pneumonia (SAP) is the one that accounts for the highest impact on stroke outcome, so research is focused on its early diagnosis and prevention. Biomarkers indicating modifications in SIIS pathways could have an important role in the early prediction of SAP, but currently, there are no individual biomarkers or panels of biomarkers that are accurate enough to be translated to clinical practice. Similarly, there is still no efficient therapy to prevent the onset of SAP, and clinical trials testing prophylactic antibiotic treatment and β-blockers have failed. However, local immunomodulation could open up a new research opportunity to find a preventive therapy for SAP. Recent studies have focused on the pulmonary immune changes that could be caused by stroke similarly to other acquired brain injuries. Some of the traits observed in animal models of stroke include lung edema and inflammation, as well as inflammation of the bronchoalveolar lavage fluid., This project received funding from Instituto de Salud Carlos III (ISCIII) [PI17/02130], co-financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ [RD16/0019/0021].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

  • Marazuela Fuentes, Paula
  • Solé Piñol, Montserrat
  • Bonaterra Pastra, Anna
  • Pizarro Gonzálvez, Jesús
  • Camacho Soriano, Jessica
  • Martinez Saez, Elena Antima
  • Castillo Ribelles, Laura
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Biomarcadors; Microdissecció de captura làser, Alzheimer's disease; Biomarkers; Laser capture microdissection, Enfermedad de Alzheimer; Biomarcadores; Microdisección por captura láser, Brain accumulation of amyloid-beta (Aβ) is a crucial feature in Alzheimer´s disease (AD) and cerebral amyloid angiopathy (CAA), although the pathophysiological relationship between these diseases remains unclear. Numerous proteins are associated with Aβ deposited in parenchymal plaques and/or cerebral vessels. We hypothesized that the study of these proteins would increase our understanding of the overlap and biological differences between these two pathologies and may yield new diagnostic tools and specific therapeutic targets. We used a laser capture microdissection approach combined with mass spectrometry in the APP23 transgenic mouse model of cerebral-β-amyloidosis to specifically identify vascular Aβ-associated proteins. We focused on one of the main proteins detected in the Aβ-affected cerebrovasculature: MFG-E8 (milk fat globule-EGF factor 8), also known as lactadherin. We first validated the presence of MFG-E8 in mouse and human brains. Immunofluorescence and immunoblotting studies revealed that MFG-E8 brain levels were higher in APP23 mice than in WT mice. Furthermore, MFG-E8 was strongly detected in Aβ-positive vessels in human postmortem CAA brains, whereas MFG-E8 was not present in parenchymal Aβ deposits. Levels of MFG-E8 were additionally analysed in serum and cerebrospinal fluid (CSF) from patients diagnosed with CAA, patients with AD and control subjects. Whereas no differences were found in MFG-E8 serum levels between groups, MFG-E8 concentration was significantly lower in the CSF of CAA patients compared to controls and AD patients. Finally, in human vascular smooth muscle cells MFG-E8 was protective against the toxic effects of the treatment with the Aβ40 peptide containing the Dutch mutation. In summary, our study shows that MFG-E8 is highly associated with CAA pathology and highlights MFG-E8 as a new CSF biomarker that could potentially be used to differentiate cerebrovascular Aβ pathology from parenchymal Aβ deposition., This work was funded by the Instituto de Salud Carlos III (ISCIII), (PI20/00465), co-financed by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS + network, ISCIII, Spain (RD16/0019/0021). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute. MMV is supported by the BIONIC project (no. 733050822, which has been made possible by ZonMW as part of ‘Memorabel’, the research and innovation program for dementia, as part of the Dutch national ‘Deltaplan for Dementia’:the CAFÉ project (the National Institutes of Health, USA, grant number 5R01NS104147-02), and a grant from the Selfridges Group Foundation (NR170024). The BIONIC project is a consortium of Radboudumc, LUMC, ADX Neurosciences, and Rhode Island University.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Reverté, Silvia
  • Garcia Berrocoso, Teresa
  • Millán Torné, Mònica
  • Castellanos, Mar
  • Ventura Ripoll, Oriol
  • Rubiera Del Fueyo, Marta Aurora
  • Montaner Villalonga, Joan
Biomarkers; Stroke; Stroke‐associated infection, Biomarcadors; Ictus; Infecció associada a un ictus, Biomarcadores; Ictus; Infección asociada a un ictus, Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life‐threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty‐eight patients experiencing ischemic stroke were prospectively recruited in the Stroke‐Chip study. Post‐stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log‐transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10‐fold cross‐validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three‐biomarker panels were developed as predictors: vascular adhesion protein‐1 >5.67, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) >4.98 and d‐dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin‐6 >3.97, von Willebrand factor >3.67, and d‐dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3–52.2]; panel for RTI: OR, 3.73 [1.95–7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea., This project received funding from Instituto de Salud Carlos III (ISCIII) [DTS14/00004, PI17/02130], co‐financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706] and the European Union's Horizon 2020 research and innovation program [754517]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ (RD16/0019/0021). The funders had no role in the study design and conduction.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer’s Disease

  • Unzeta, Mercedes
  • Hernandez Guillamon, Maria Mar
  • Sun, Ping
  • Solé Piñol, Montserrat
Alzheimer’s disease; Inflammation; Vascular damage, Malaltia d'Alzheimer; Inflamació; Lesions vasculars, Enfermedad de Alzheimer; Inflamación; Lesión vascular, The semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1) or primary amine oxidase (PrAO), is a deaminating enzyme highly expressed in vessels that generates harmful products as a result of its enzymatic activity. As a multifunctional enzyme, it is also involved in inflammation through its ability to bind and promote the transmigration of circulating leukocytes into inflamed tissues. Inflammation is present in different systemic and cerebral diseases, including stroke and Alzheimer’s disease (AD). These pathologies show important affectations on cerebral vessels, together with increased SSAO levels. This review summarizes the main roles of SSAO/VAP-1 in human physiology and pathophysiology and discusses the mechanisms by which it can affect the onset and progression of both stroke and AD. As there is an evident interrelationship between stroke and AD, basically through the vascular system dysfunction, the possibility that SSAO/VAP-1 could be involved in the transition between these two pathologies is suggested. Hence, its inhibition is proposed to be an interesting therapeutical approach to the brain damage induced in these both cerebral pathologies., This research received no external funding. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Blood flow response to orthostatic challenge identifies signatures of the failure of static cerebral autoregulation in patients with cerebrovascular disease

  • Gregori-Pla, Clara
  • Mesquita, Rickson C.
  • Favilla, Christopher G.
  • Busch, David R.
  • Blanco, Igor
  • Zirak, Peyman
  • Maruccia, Federica
Autorregulació cerebral; Malaltia cerebrovascular; Òptica difusa, Autorregulación cerebral; Enfermedad cerebrovascular; Óptica difusa, Cerebral autoregulation; Cerebrovascular disease; Diffuse optics, Background The cortical microvascular cerebral blood flow response (CBF) to different changes in head-of-bed (HOB) position has been shown to be altered in acute ischemic stroke (AIS) by diffuse correlation spectroscopy (DCS) technique. However, the relationship between these relative ΔCBF changes and associated systemic blood pressure changes has not been studied, even though blood pressure is a major driver of cerebral blood flow. Methods Transcranial DCS data from four studies measuring bilateral frontal microvascular cerebral blood flow in healthy controls (n = 15), patients with asymptomatic severe internal carotid artery stenosis (ICA, n = 27), and patients with acute ischemic stroke (AIS, n = 72) were aggregated. DCS-measured CBF was measured in response to a short head-of-bed (HOB) position manipulation protocol (supine/elevated/supine, 5 min at each position). In a sub-group (AIS, n = 26; ICA, n = 14; control, n = 15), mean arterial pressure (MAP) was measured dynamically during the protocol. Results After elevated positioning, DCS CBF returned to baseline supine values in controls (p = 0.890) but not in patients with AIS (9.6% [6.0,13.3], mean 95% CI, p < 0.001) or ICA stenosis (8.6% [3.1,14.0], p = 0.003)). MAP in AIS patients did not return to baseline values (2.6 mmHg [0.5, 4.7], p = 0.018), but in ICA stenosis patients and controls did. Instead ipsilesional but not contralesional CBF was correlated with MAP (AIS 6.0%/mmHg [− 2.4,14.3], p = 0.038; ICA stenosis 11.0%/mmHg [2.4,19.5], p < 0.001). Conclusions The observed associations between ipsilateral CBF and MAP suggest that short HOB position changes may elicit deficits in cerebral autoregulation in cerebrovascular disorders. Additional research is required to further characterize this phenomenon., The funders did not have any role in study design, execution and data interpretation. This work was funded by Redes Temáticas de Investigación Cooperativa (RETICS-INVICTUS RD012/0014 and RD16/0019/0010), Fundació CELLEX Barcelona, Ministerio de Economía y Competitividad/FEDER (PHOTODEMENTIA, PHOTOMETABO, DPI2015–64358-C2–1-R, PRE2018-085082), Instituto de Salud Carlos III/FEDER (FIS PI09/0557, MEDPHOTAGE, DTS16/00087), the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2015-0522), the Obra Social “la Caixa” Foundation (LlumMedBcn), Institució “Centres de Recerca de Catalunya”, “Agència de Gestió d’Ajuts Universitaris i de Recerca”-Generalitat (2017SGR-1380), LASERLAB-EUROPE IV (EU-H2020 654148), Whitaker International Program of the Institute for International Education, T32 HL007954 Multidisciplinary training in cardiovascular biology, Marie Curie initial training network (OILTEBIA 317526), Marie Sklowdowska-Curie-COFUND (H2020, ICFOstepstone 2, 71329), “Fundació La Marató TV3” (201709.30, 201709.31), São Paulo Research Foundation (FAPESP) through 2012/02500–8 and National Institutes of Health (R01-NS060653, K24-NS058386, R24-HD050836, P41-EB015893, DP2-HD101400, U54-HD086984).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization

  • Aliena-Valero, Alicia
  • Hernández Jiménez, Macarena
  • López Morales, Mikahela
  • Tamayo-Torres, Eva
  • Castelló-Ruiz, Maria
  • Piñeiro, David
  • Ribo, Marc
Aptamers; Cerebroprotection; Ischemic stroke, Aptàmers; Cerebroprotecció; Ictus isquèmic, Aptámeros; Cerebroprotección; Ictus isquémico, ApTOLL, a TLR4 modulator aptamer, has demonstrated cerebroprotective effects in a permanent ischemic stroke mouse model, as well as safety and efficacy in early phase clinical trials. We carried out reverse translation research according to STAIR recommendations to further characterize the effects and mechanisms of ApTOLL after transient ischemic stroke in rats and to better inform the design of pivotal clinical trials. Adult male rats subjected to transient middle cerebral artery occlusion were treated either with ApTOLL or the vehicle intravenously at different doses and time-points. ApTOLL was compared with TAK-242 (a TLR4 inhibitor). Female rats were also studied. After neurofunctional evaluation, brains were removed for infarct/edema volume, hemorrhagic transformation, and histologic determinations. Peripheral leukocyte populations were assessed via flow cytometry. ApTOLL showed U-shaped dose-dependent cerebroprotective effects. The maximum effective dose (0.45 mg/kg) was cerebroprotective when given both before reperfusion and up to 12 h after reperfusion and reduced the hemorrhagic risk. Similar effects occurred in female rats. Both research and clinical ApTOLL batches induced slightly superior cerebroprotection when compared with TAK-242. Finally, ApTOLL modulated circulating leukocyte levels, reached the brain ischemic tissue to bind resident and infiltrated cell types, and reduced the neutrophil density. These results show the cerebroprotective effects of ApTOLL in ischemic stroke by reducing the infarct/edema volume, neurofunctional impairment, and hemorrhagic risk, as well as the peripheral and local immune response. They provide information about ApTOLL dose effects and its therapeutic time window and target population, as well as its mode of action, which should be considered in the design of pivotal clinical trials., This study was sponsored by AptaTargets S.L. (Madrid, Spain) and co-funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTC-2019-006795-1), Centro para el Desarrollo Tecnológico Industrial (IDI-20210746), and Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”) (RD16/0019/0008 and RD21/0006/0014). The funders were not involved in the study design; collection, analysis, or interpretation of data; the writing of this article; or the decision to submit it for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease

  • Camacho Soriano, Jessica
  • Rábano, Alberto
  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Serna Alonso, Garazi
  • Moline Marimon, Teresa
  • Ramon y Cajal Agüeras, Santiago
  • Martinez Saez, Elena Antima
  • Hernandez Guillamon, Maria Mar
Alzheimer; CD2AP; Enfermedad de Pick, Alzheimer's disease; CD2AP; Pick's disease, Alzheimer; CD2AP; Malaltia de Pick, Genome-wide association studies have described several genes as genetic susceptibility loci for Alzheimer's disease (AD). Among them, CD2AP encodes CD2-associated protein, a scaffold protein implicated in dynamic actin remodeling and membrane trafficking during endocytosis and cytokinesis. Although a clear link between CD2AP defects and glomerular pathology has been described, little is known about the function of CD2AP in the brain. The aim of this study was to analyze the distribution of CD2AP in the AD brain and its potential associations with tau aggregation and β-amyloid (Aβ) deposition. First, we performed immunohistochemical analysis of CD2AP expression in brain tissue from AD patients and controls (N = 60). Our results showed granular CD2AP immunoreactivity in the human brain endothelium in all samples. In AD cases, no CD2AP was found to be associated with Aβ deposits in vessels or parenchymal plaques. CD2AP neuronal inclusions similar to neurofibrillary tangles (NFT) and neuropil thread-like deposits were found only in AD samples. Moreover, immunofluorescence analysis revealed that CD2AP colocalized with pTau. Regarding CD2AP neuronal distribution, a hierarchical progression from the entorhinal to the temporal and occipital cortex was detected. We found that CD2AP immunodetection in neurons was strongly and positively associated with Braak neurofibrillary stage, independent of age and other pathological hallmarks. To further investigate the association between pTau and CD2AP, we included samples from cases of primary tauopathies (corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], and Pick's disease [PiD]) in our study. Among these cases, CD2AP positivity was only found in PiD samples as neurofibrillary tangle-like and Pick body-like deposits, whereas no neuronal CD2AP deposits were detected in PSP or CBD samples, which suggested an association of CD2AP neuronal expression with 3R-Tau-diseases. In conclusion, our findings open a new road to investigate the complex cellular mechanism underlying the tangle conformation and tau pathology in the brain., This work was funded by Instituto de Salud Carlos III (ISCIII) (PI17/00275, PI20/00465), cofinanced by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. is supported by the Miguel Servet Programme, ISCIII, Spain (CPII17/00010)
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Faura Llorens, Julia
  • Penalba Morenilla, Anna
  • Pizarro Gonzálvez, Jesús
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Vert Soler, Carla
  • Rovira, Alex
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Aquaporina 4; Angiopatia amiloide cerebral; Marcadors d'imatge per ressonància magnètica, Acuaporina 4; Angiopatía amiloide cerebral; Marcadores de imágenes por resonancia magnética, Aquaporin 4; Cerebral amyloid angiopathy; Magnetic resonance imaging markers, Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH., This research was funded by the Instituto de Salud Carlos III (ISCIII), (PI17/00275 and PI20/00465), co-financed by the European Regional Development Fund FEDER. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. was supported by the Miguel Servet programme, ISCIII, Spain (CPII17/00010). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Functional Recovery and Serum Angiogenin Changes According to Intensity of Rehabilitation Therapy After Stroke

  • Garcia Rodriguez, Nicolas
  • Rodriguez Gonzalez, Susana
  • Ignacio Tejada, Pedro
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez Bazan, Laura Mónica
  • Quintana Luque, Manuel
  • Olive Gadea, Marta
  • Penalba Morenilla, Anna
  • Rosell Novel, Anna
  • Inzitari, Marco
  • Perez-Mesquida, Maria Engracia
Angiogenina; Terapia intensiva; Rehabilitación, Angiogenin; Intensive therapy; Rehabilitation, Angiogenina; Teràpia intensiva; Rehabilitació, Background: Rehabilitation is still the only treatment available to improve functional status after the acute phase of stroke. Most clinical guidelines highlight the need to design rehabilitation treatments considering starting time, intensity, and frequency, according to the tolerance of the patient. However, there are no homogeneous protocols and the biological effects are under investigation. Objective: To investigate the impact of rehabilitation intensity (hours) after stroke on functional improvement and serum angiogenin (ANG) in a 6-month follow-up study. Methods: A prospective, observational, longitudinal, and multicenter study with three cohorts: strokes in intensive rehabilitation therapy (IRT, minimum 15 h/week) vs. conventional therapy (NO-IRT, <15 h/week), and controls subjects (without known neurological, malignant, or inflammatory diseases). A total of seven centers participated, with functional evaluations and blood sampling during follow-up. The final cohort includes 62 strokes and 43 controls with demographic, clinical, blood samples, and exhaustive functional monitoring. Results: The median (IQR) number of weekly hours of therapy was different: IRT 15 (15–16) vs. NO-IRT 7.5 (5–9), p < 0.01, with progressive and significant improvements in both groups. However, IRT patients showed earlier improvements (within 1 month) on several scales (CAHAI, FMA, and FAC; p < 0.001) and the earliest community ambulation achievements (0.89 m/s at 3 months). There was a significant difference in ANG temporal profile between the IRT and NO-IRT groups (p < 0.01). Additionally, ANG was elevated at 1 month only in the IRT group (p < 0.05) whereas it decreased in the NO-IRT group (p < 0.05). Conclusions: Our results suggest an association of rehabilitation intensity with early functional improvements, and connect the rehabilitation process with blood biomarkers., NG-R holds a VHIR fellowship and MO-G a Joan Margarit VHIR fellowship. Research grants: from the Instituto de Salud Carlos III and European Regional Development Funds (PI16/00981, PI19/00186, RD16/0019/0021, and RD16/0019/0008), 2017-SGR-1427 program from the Generalitat de Catalunya-AGAUR, and Clinical Translational Program for Regenerative Medicine in Catalonia (P-CMR [C]).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke

  • Ramiro Pascual, Laura
  • Quintana Luque, Manuel
  • Garcia Rodriguez, Paula
  • Santamarina Pérez, Estevo
  • Alvarez Sabin, José
  • Bustamante Rangel, Alejandro
  • Montaner Villalonga, Joan
  • Abraira del Fresno, Laura
Biomarcador; Endostatina; Accident cerebrovascular isquèmic, Biomarcador; Endostatina; Accidente cerebrovascular isquémico, Biomarker; Endostatin; Ischemic stroke, Stroke is a major cause of disability and death globally, and prediction of mortality represents a crucial challenge. We aimed to identify blood biomarkers measured during acute ischemic stroke that could predict long-term mortality. Nine hundred and forty-one ischemic stroke patients were prospectively recruited in the Stroke-Chip study. Post-stroke mortality was evaluated during a median 4.8-year follow-up. A 14-biomarker panel was analyzed by immunoassays in blood samples obtained at hospital admission. Biomarkers were normalized and standardized using Z-scores. Multiple Cox regression models were used to identify clinical variables and biomarkers independently associated with long-term mortality and mortality due to stroke. In the multivariate analysis, the independent predictors of long-term mortality were age, female sex, hypertension, glycemia, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Independent blood biomarkers predictive of long-term mortality were endostatin > quartile 2, tumor necrosis factor receptor-1 (TNF-R1) > quartile 2, and interleukin (IL)-6 > quartile 2. The risk of mortality when these three biomarkers were combined increased up to 69%. The addition of the biomarkers to clinical predictors improved the discrimination (integrative discriminative improvement (IDI) 0.022 (0.007–0.048), p < 0.001). Moreover, endostatin > quartile 3 was an independent predictor of mortality due to stroke. Altogether, endostatin, TNF-R1, and IL-6 circulating levels may aid in long-term mortality prediction after stroke., This work has been funded by Instituto de Salud Carlos III (PI18/00804) and by La Fundació La Marató (Reg. 84/240 proj. 201702). Neurovascular Research Laboratory takes part in the Spanish stroke research network INVICTUS+ (RD16/0019/0021). L.R. is supported by a pre-doctoral fellowship from the Instituto de Salud Carlos III (IFI17/00012).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

  • Bonaterra Pastra, Anna
  • Fernández de Retana, Sofía
  • Rivas-Urbina, Andrea
  • Puig, Núria
  • Benítez, Sònia
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Apolipoproteïnes; Angiopatia amiloide cerebral, Enfermedad de Alzheimer; Apolipoproteínas; Angiopatía amiloide cerebral, Alzheimer’s disease; Apolipoproteins; Cerebral amyloid angiopathy, Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation., This research was funded by Instituto de Salud Carlos III (co-financed by the European Regional Development Fund FEDER “Una manera de hacer Europa”), grant numbers PI13/00364, PI16/00471, PI14/01134 and PI17/00275. A.R.-U. was funded by Instituto de Salud Carlos III predoctoral contract FI17/00031. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain [RD16/0019/0021]. J.L.S.-Q. is a member of the CIBER of Diabetes and Metabolism (CIBERDEM), ISCIII, Spain. M.H.-G. is supported by the Miguel Servet programme, ISCIII, Spain [CPII17/00010]. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Quality Research Group 2017-SGR-1149 from Generalitat de Catalunya. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Group of Vascular Biology from the Spanish Atherosclerosis Society.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Identifying new blood biomarkers of neuroplasticity associated with rehabilitation outcomes after stroke

  • García Rodríguez, Nicolás
  • García-Gabilondo, Miguel
  • Rodriguez, Susana
  • Tejada Ezquerro, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez-Mesquida, Maria Engracia
  • Valor-Blanquer, Júlia
  • Penalba Morenilla, Anna
  • Pérez, Laura Mónica
  • Inzitari, Marco
  • Lamana Vallverdú, Marcel
  • Delgado Martínez, María Pilar
  • Rosell Novel, Anna
Biomarker; Neuroplasticity; Recovery, Biomarcador; Neuroplasticitat; Recuperació, Biomarcador; Neuroplasticidad; Recuperación, Blood biomarkers in stroke patients seek to guide decision-making in clinical practice, but research on those that respond to brain recovery and their relationship with rehabilitation is still limited. Our aim was to explore the value of known neuroplasticity-related molecules, such as endostatin, growth and differentiation factor-10 (GDF-10), urokinase-type plasminogen activator (uPA) and the uPA receptor (uPAR), as blood biomarkers of recovery during poststroke rehabilitation. In an observational, prospective and multicenter study, biomarker levels were assessed after stroke in a cohort of 62 stroke patients with outcome evaluations and blood sampling before starting rehabilitation and during therapy at 1, 3 and 6 months of first visit, and in 43 control subjects. Serum levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) together with a complete battery of sensorimotor and functional tests/scales: modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA) for the upper extremity, Functional Ambulation Categories (FAC), Chedoke Arm and Hand Activity Inventory (CAHAI), 10-m walk test and the Medical Research Council (MRC). Statistical mixed linear models were built to investigate its prognostic value. The results revealed that, compared to controls, only endostatin was significantly increased at baseline after stroke (p < 0.01). Interestingly, the highest baseline GDF-10 or uPAR values were related to unfavorable scores during the complete follow-up (p < 0.05 for walking speed or MRC with GDF-10, and for FMA or MRC with uPAR), whereas decreased endostatin or increased GDF-10 biomarker changes at first month of rehabilitation were related to greater sensorimotor and functional improvements during follow-up (p < 0.05 for FMA or MRC with endostatin, and CAHAI or BI with GDF-10). Our results position endostatin, GDF-10 and uPAR as potential blood biomarkers to monitor recovery during rehabilitation after stroke., N.G-R. is doing a doctorate at the Departament de Medicina de la Universitat Autònoma de Barcelona. Research grants from the Instituto de Salud Carlos III with European Regional Development or Next Generation Founds to A.R. or J.B.S. supported this study (PI16/00981, PI19/00186, RD16/0019/0021, RD16/0019/0008, RD21/0006/0007, and RD21/0006/0014), as well as the 2021-SGR-0656 programme from the Generalitat de Catalunya-AGAUR. N.G-R. received a predoctoral fellowship from VHIR, and MG-G. received a research support grant (PERIS, SLT017/20/000197).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Survival Bias and Crosstalk between Chronological and Behavioral Age: Age- and Genotype-Sensitivity Tests Define Behavioral Signatures in Middle-Aged, Old, and Long-Lived Mice with Normal and AD-Associated Aging

  • Marin-Pardo, Daniela
  • Marazuela Fuentes, Paula
  • Hernandez Guillamon, Maria Mar
  • Giménez-Llort, Lydia
Malaltia d'Alzheimer; Envelliment; Supervivència, Alzheimer’s disease; Aging; Survival, Enfermedad de Alzheimer; Envejecimiento; Supervivencia, New evidence refers to a high degree of heterogeneity in normal but also Alzheimer’s disease (AD) clinical and temporal patterns, increased mortality, and the need to find specific end-of-life prognosticators. This heterogeneity is scarcely explored in very old male AD mice models due to their reduced survival. In the present work, using 915 (432 APP23 and 483 C57BL/6 littermates) mice, we confirmed the better survival curves in male than female APP23 mice and respective wildtypes, providing the chance to characterize behavioral signatures in middle-aged, old, and long-lived male animals. The sensitivity of a battery of seven paradigms for comprehensive screening of motor (activity and gait analysis), neuropsychiatric and cognitive symptoms was analyzed using a cohort of 56 animals, composed of 12-, 18- and 24-month-old male APP23 mice and wildtype littermates. Most variables analyzed detected age-related differences. However, variables related to coping with stress, thigmotaxis, frailty, gait, and poor cognition better discriminated the behavioral phenotype of male APP23 mice through the three old ages compared with controls. Most importantly, non-linear age- and genotype-dependent behavioral signatures were found in long-lived animals, suggesting crosstalk between chronological and biological/behavioral ages useful to study underlying mechanisms and distinct compensations through physiological and AD-associated aging., This work was funded by the BrightFocus Foundation, US (A2017243S). The Neurovascular Research Laboratory is part of the INVICTUS+network, Instituto de Salud Carlos III (ISCIII), Spain [RD16/0019/0021], co-financed by the European Regional Development Fund FEDER. P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Angiogenin in the Neurogenic Subventricular Zone After Stroke

  • Gabriel Salazar, Marina
  • Lei (Santiago), Ting
  • Grayston Morales, Alba
  • Costa Riu, Carme
  • Medina Gutierrez, Esperanza
  • Montaner Villalonga, Joan
  • Rosell Novel, Anna
  • Comabella Lopez, Manuel
Angiogenina; Exercici; Neuroreparació, Angiogenina; Ejercicio; Neuroreparación, Angiogenin; Exercise; Neurorepair, Ischemic stroke is a leading cause of death and disability worldwide with effective acute thrombolytic treatments. However, brain repair mechanisms related to spontaneous or rehabilitation-induced recovery are still under investigation, and little is known about the molecules involved. The present study examines the potential role of angiogenin (ANG), a known regulator of cell function and metabolism linked to neurological disorders, focusing in the neurogenic subventricular zone (SVZ). Angiogenin expression was examined in the mouse SVZ and in SVZ-derived neural stem cells (NSCs), which were exposed to exogenous ANG treatment during neurosphere formation as well as in other neuron-like cells (SH-SY5Y). Additionally, male C57Bl/6 mice underwent a distal permanent occlusion of the middle cerebral artery to study endogenous and exercise-induced expression of SVZ-ANG and neuroblast migration. Our results show that SVZ areas are rich in ANG, primarily expressed in DCX+ neuroblasts but not in nestin+NSCs. In vitro, treatment with ANG increased the number of SVZ-derived NSCs forming neurospheres but could not modify SH-SY5Y neurite differentiation. Finally, physical exercise rapidly increased the amount of endogenous ANG in the ipsilateral SVZ niche after ischemia, where DCX-migrating cells increased as part of the post-stroke neurogenesis process. Our findings position for the first time ANG in the SVZ during post-stroke recovery, which could be linked to neurogenesis., MG-S was supported by a pre-doctoral fellowship from the Vall d'Hebron Research Institute, AR was supported by the Miguel Servet program and AG holds a pre-doctoral fellowship both from Instituto Carlos III (CPII15/00003 and FI17/00073, respectively), and TL was supported by the China Scholarship Council (CSC-201706170048). This research has been funded by grants PI16/00981, PI19/00186, and RD16/0019/0021 (RETICS-INVICTUS PLUS) from the Instituto de Salud Carlos III co-financed by the European Regional Development Funds, and by the Generalitat de Catalunya (2017SGR 1427).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Integrative multi-omics analysis for etiology classification and biomarker discovery in stroke: advancing towards precision medicine

  • Labarga Gutiérrez, Alberto
  • Martínez-González, Judith
  • Barajas Vélez, Miguel Ángel
Recent advancements in high-throughput omics technologies have opened new avenues for investigating stroke at the molecular level and elucidating the intricate interactions among various molecular components. We present a novel approach for multi-omics data integration on knowledge graphs and have applied it to a stroke etiology classification task of 30 stroke patients through the integrative analysis of DNA methylation and mRNA, miRNA, and circRNA. This approach has demonstrated promising performance as compared to other existing single technology approaches., This work was supported by Navarre Government Funding (Industry and Health department) through ADITECH and by RED INVICTUS (RD16/0019/0024) from the Institute of Health Carlos III, jointly funded by European Regional Development Fund (ERDF), European Union.